Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 23677. Отображено 100.
08-07-2019 дата публикации

Двухместная полимерная форма для изготовления контрольных образцов бетона с возможностью ультразвукового исследования

Номер: RU0000190657U1
Автор: Анна Олеговна Крюкова, Антон Сергеевич Пилипенко, Валентин Петрович Горбачевский, Дарья Владиславовна Громова, Мухамед Заурович Хапов, Сайыына Сергеевна Степанова, Сергей Иванович Пилипенко
Принадлежит: Антон Сергеевич Пилипенко

Полезная модель относится к технике испытания материалов и может быть использована для изготовления контрольных образцов бетона. Заявленная форма состоит из поддона, стенок и съемной перегородки, выполненных из прозрачного пластика, в стенки формы встроены ультразвуковые преобразователи, а крепежные элементы выполнены в виде поворотных крючковых элементов Технический результат - повышение качества получаемых образцов, обеспечение возможности динамического наблюдения за процессом набора прочности образцами, а также снижение времени чистки и подготовки форм. Прозрачность стенок дает возможность наблюдения за качеством наполнения формы и процессом образования структуры образца, а ультразвуковые преобразователи, непосредственно прилегающие к бетонной смеси, позволяют динамически оценивать параметры набора прочности образцов бетона ультразвуковым методом. Применение полимерных компонентов формы за счет пониженной адгезии их к бетону позволяет упростить (и в некоторых случаях исключить) операцию смазки формы и снизить время последующей чистки, также рабочая поверхность ультразвуковых преобразователей может быть очищена методом кавитационной очистки ультразвуком в наполненной водой форме. РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 190 657 U1 (51) МПК B28B 7/24 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ПОЛЕЗНОЙ МОДЕЛИ К ПАТЕНТУ (52) СПК B28B 7/24 (2019.02); G01N 33/68 (2019.02) (21)(22) Заявка: 2018146991, 27.12.2018 (24) Дата начала отсчета срока действия патента: Дата регистрации: 08.07.2019 (73) Патентообладатель(и): Пилипенко Антон Сергеевич (RU) (45) Опубликовано: 08.07.2019 Бюл. № 19 1 9 0 6 5 7 R U (56) Список документов, цитированных в отчете о поиске: SU 1682174 A1, 07.10.1991. SU 1135657 A1, 23.01.1985. SU 1012132 A1, 15.04.1983. RU 2558852 C1, 10.08.2015. RU 2243888 C2, 10.01.2005. US 20090146043 A1, 11.06.2009. (54) ДВУХМЕСТНАЯ ПОЛИМЕРНАЯ ФОРМА ДЛЯ ИЗГОТОВЛЕНИЯ КОНТРОЛЬНЫХ ОБРАЗЦОВ БЕТОНА С ВОЗМОЖНОСТЬЮ УЛЬТРАЗВУКОВОГО ИССЛЕДОВАНИЯ ...

Подробнее
Номер записи: 1
19-01-2012 дата публикации

Anti-polyethylene glycol antibody expressing cell quantify any free polyethylene glycol and polyethylene glycol-derivatized molecules

Номер: US20120015380A1
Автор: Kuo-Hsiang Chuang, Ssu-Jung Lu, Steven R. Roffler, Tian-Lu Cheng
Принадлежит: KAOHSIUNG MEDICAL UNIVERSITY

In this invention, anti-PEG antibodies or anti-methoxyl-PEG (anti-CH 3 O-PEG) antibodies were expressed on cell surface which can collocate with a biotinylated anti-PEG antibody (AGP4-Biotin) or biotinylated PEG (PEG-Biotin) to develop a cell-based sandwich ELISA or a cell-based competition ELISA, respectively. Both of these two methods could sensitively quantify free PEG and PEG-modified macromolecules (proteins, nanoparticles and liposomes) as sensitive as nano-gram level.

Подробнее
Номер записи: 2
02-02-2012 дата публикации

Formation and encapsulation of molecular bilayer and monolayer membranes

Номер: US20120025414A1
Автор: Jacob J. Schmidt, Jason Poulos, Noah Malmstadt, Tae-Joon Jeon
Принадлежит: UNIVERSITY OF CALIFORNIA

Disclosed herein are compositions, methods, and devices related to bilayer and monolayer membranes, their encapsulation in a hydrogel, and their formation. Methods of using the disclosed compositions and devices are also disclosed.

Подробнее
Номер записи: 3
09-02-2012 дата публикации

Beverage disguise for hand held breathalyzer interface of ignition interlock device

Номер: US20120031166A1
Автор: Davin E. Lopez, Luis M. Ortiz
Принадлежит: Mesa Digital LLC

A breath alcohol ignition interlock device includes a mock beverage housing including at least one of breath alcohol electronics and a hand held breath alcohol analyzer therein, a mouthpiece in fluid communication with an alcohol sensor associated with the at least one of breath alcohol electronics and a hand held breath alcohol analyzer and a vent exhausting breath from the mock beverage housing. The mock beverage container housing can be disguised as a coffee cup, a fountain drink cup, a soda can and a soft drink bottle. The mouthpiece can be disguised as a coffee cup lid, a fountain drink cup straw, a soda can opening and a soft drink bottle top. A wireless communication module can support data synchronization and communications between the device and a base station installed within a motor vehicle.

Подробнее
Номер записи: 4
16-02-2012 дата публикации

Methods of classifying the severity of diseases or disorders

Номер: US20120040354A1
Автор: Borge Gronne Nordestgaard, Hans Jorgen Nielsen, Ib Jarle Christensen, Julia Sidenius Johansen, Stig Bojesen
Принадлежит: Herlev Hospital Region Hovedstaden, HVIDOVRE HOSPITAL, RIGSHOSPITALET

The present invention relates to methods of classifying the severity of a non-specific disease or disorder in a subject, wherein a determined level of YKL-40 is compared to one or more reference levels of YKL-40, and the severity of said non-specific disease or disorder is deduced from said comparison. The present invention furthermore relates to a method of classifying the severity of a disease or disorder in a subject, wherein a determined level of YKL-40 is compared to one or more previously determined levels of YKL-40 from the same subject. In both methods, the subject may suffer from a variety of diseases or disorders. In addition the present invention relates to a kit and a device that may be used in the methods of the present invention comprising means for measuring the level of YKL-40 in a sample; and means for comparing the measured level of YKL-40 with one or more reference levels of YKL-40.

Подробнее
Номер записи: 5
16-02-2012 дата публикации

Method for Introducing Protein and/or Peptide Into Cell

Номер: US20120040390A1
Автор: Hidenori Yamada, Hidetaka Nakanishi, Junichiro Futami, Takashi Kai
Принадлежит: NIPPON SHOKUBAI CO LTD

The present invention provides a method of intracellular introduction by which a protein and/or peptide can be efficiently introduced into living cells and which makes it possible to effectively analyze the behavior and function of the protein and/or peptide introduced and can be suitably utilized/applied, for example in the technology “live cell imaging” which realizes the immunohistochemical visualization in living cells under physiological conditions. The method of intracellular introduction is a method for introducing a protein and/or peptide into a cell, which comprises the process of introducing a conjugate generated by binding of a compound adsorbable on a cell surface to a protein and/or peptide via a polysulfide bond into a cell and treating with a reducing agent.

Подробнее
Номер записи: 6
01-03-2012 дата публикации

Reagent kit for detecting lupus anticoagulant and method of determining presence or absence of lupus anticoagulant

Номер: US20120052585A1
Автор: Kazuyo Yoshida, Masahiro Okuda, Osamu Kumano
Принадлежит: Sysmex Corp

The present invention provides a reagent kit for detecting LA which includes a first clotting time-measuring reagent containing manganese salt and a second clotting time-measuring reagent which contains manganese salt at a concentration lower than that of the first clotting time-measuring reagent or does not contain manganese salt and a method of determining the presence or absence of LA using the kit.

Подробнее
Номер записи: 7
08-03-2012 дата публикации

Use of megalin in urine as marker for detecting renal disorder

Номер: US20120058489A1
Автор: Akihiko Saito, Hiroyuki Kurosawa, Katsuhiko Asanuma, Shinya Ogaswara, Yasuhiko Tomino, Yoshiaki Hirayama
Принадлежит: Denka Seiken Co Ltd, Juntendo Educational Foundation, Niigata University NUC

This invention provides a simple means for detecting a renal disorder, a diagnostic marker for a renal disorder that enables prognostic prediction of a renal disorder (e.g., diabetic nephropathy and IgA nephropathy) and evaluation of the degree of nephropathy at the phase of stage-II diabetic nephropathy by measuring the megalin level in urine associated with a renal disorder used for the detection means, and use of such marker. The invention also provides the use of human megalin obtained from the urine sample of a subject as a marker for detecting a renal disorder.

Подробнее
Номер записи: 8
08-03-2012 дата публикации

Test kit and method for measurement of metals in biological fluids

Номер: US20120058564A1
Автор: Karmakar Nivedita Gohil, Manisha Sharma, Renu Saxena
Принадлежит: INDIAN INSTITUTE OF TECHNOLOGY DELHI

A test kit and a biomedical process is provided to estimate metals particularly non-transferrin bound iron levels (NTBI) in circulating body fluids particularly, serum. NTBI appears in serum when there is excess iron in the body. The method comprises of employing a signal generating moiety capable of complexing with iron that is a peptide like molecule having an iron binding site and also an optical signal generating functional group. The molecule is of microbial origin. The measurement is based on the alteration of optical characteristics of the probe molecule upon attachment of iron to its binding site on the molecule. Hence it generates a signal proportionate to the amount of iron available for binding and provides a direct estimate of free or unbound iron in the sample. According to this instant invention a rapid estimation method of NTBI in body fluids can be undertaken in an inexpensive way without the need of specialized expertise.

Подробнее
Номер записи: 9
08-03-2012 дата публикации

Drug target that promotes secretory granule-granule fusion

Номер: US20120058931A1
Автор: Haruo Kasai, Herbert Y. Gaisano, Noriko Takahashi, Patrick Lam, Vesa Olkkonen
Принадлежит: Individual

Munc18 proteins facilitate formation of SNARE complexes known to mediate membrane fusion. Much is known about the fusion of secretory granule (SG) to plasma membrane, mediated by Munc18a-SNARE complexes. It has been found that another Munc18 isoform, Munc18b, mediates SG-SG fusion which causes potentiation of secretion. The present invention has identified specific site mutations within Munc18b which further increased (called KR mutant) or reduced (called E59K mutant) SG-SG fusion compared to wild type (WT) Munc18b, causing amplification or reduction of insulin secretion, respectively. Compounds identified that mimic the actions of Munc18b-WT and Munc18b-KR mutant which increase SG-SG fusion, and those which mimic Munc18b-E59K mutant that block SG-SG fusion, are useful for treating and/or preventing diseases and/or conditions, whose underlying bases are a deficiency or excess of SG-SG fusion, respectively. These compounds also include conserved domains in Munc18a and Munc18c that mimic the KR and E59K sites in Munc18b.

Подробнее
Номер записи: 10
15-03-2012 дата публикации

Progesterone receptor membrane component 1 (PGRMC1) as an indicator of fertility in animals

Номер: US20120060767A1
Автор: John J. Peluso
Принадлежит: University of Connecticut

Methods of evaluating fertility of an animal based on determination of a PGRMC1 characteristic that correlates with animal fertility. In one embodiment, a sample is obtained from an animal, a PGRMC1 characteristic is determined and compared to a baseline PGRMC1 characteristic, wherein a variation between the determined PGRMC1 characteristic and the baseline characteristic indicates a level of fertility of the animal. A PGRMC1 characteristic can be one or more of PGRMC1 expression, transcription, translation, amino acid sequence, nucleic acid sequence, post-translational modification, cell localization or tissue localization. A sample can be a cell sample, a tissue sample, a blood sample, a lymphocyte sample, an oocyte sample, or a sperm sample. The animal can be male or female. In one embodiment, a variation of PGRMC1 nucleic acid sequence indicates reduced fertility of the animal.

Подробнее
Номер записи: 11
22-03-2012 дата публикации

Methods

Номер: US20120071337A1
Автор: Andreas Christian GÜNTERT, Darragh P.W. O'Brien, Helen Louise Byers, James Campbell, Simon Harold Lovestone
Принадлежит: Electrophoretics Ltd, KINGS COLLEGE LONDON

The invention provides a method for aiding the diagnosis or prognostic monitoring of Alzheimer's disease in a subject, said method comprising; providing a sample of blood obtained from said patient; assaying the amount of gelsolin present in said sample; comparing the amount of gelsolin present in said sample to a reference amount of gelsolin present in a sample from a healthy subject, wherein detection of a gelsolin level in the sample from said patient which is lower than the gelsolin level in the reference sample indicates an increased likelihood of Alzheimer's disease in said patient. Other markers are C1 protease inhibitor and ceruloplasmin. Both blood samples and tissue samples have been investigated.

Подробнее
Номер записи: 12
29-03-2012 дата публикации

Methods and materials for isolating exosomes

Номер: US20120077263A1
Автор: Christopher J. Ward, Marie C. Hogan, Marina Ramirez-Alvarado
Принадлежит: Mayo Foundation for Medical Education and Research

This document relates to methods and materials involved in obtaining exosomes. For example, methods and materials for obtaining exosomes from biological samples such as urine samples are provided.

Подробнее
Номер записи: 13
29-03-2012 дата публикации

Compartment-Specific Non-HLA Targets for Diagnosis and Prediction of Graft Outcome

Номер: US20120077689A1
Автор: Atul J. Butte, Minnie M. Sarwal
Принадлежит: Leland Stanford Junior University

Methods and composition are provided for diagnosing or predicting the status or the outcome of a graft transplant. In some embodiments, the presence or absence of one or more proteins recognizing a non-HLA/non ABO antigen is determined. The obtained result is then employed to diagnose or predict the status or outcome of the graft transplant. Also provided are compositions, systems and kits that find use in practicing the subject methods.

Подробнее
Номер записи: 14
19-04-2012 дата публикации

diagnostic method

Номер: US20120091333A1
Автор: Dharmica April Harridatt Mistry, Gary L. Corino, Joseph Haklani, Peter William French
Принадлежит: Sbc Research Pty Ltd

The present invention relates to methods to identify one or more conditions in a subject. In particular, it relates to methods of identifying a condition such as cancer, which changes a lipid profile in a keratin-containing component of a subject, the changes to the lipid profile being determined by techniques such as chromatography and mass spectrometry.

Подробнее
Номер записи: 15
03-05-2012 дата публикации

Analysis reagent and analysis device having the analysis reagent carried therein

Номер: US20120107850A1
Автор: Hiroshi Saiki, Kenji Ishibashi, Kenji Watanabe, Kouzou Tagashira, Yuki Maruyama
Принадлежит: Panasonic Corp

A reagent including a combination of a polyanionic compound and a bivalent cationic compound contains one substance selected from the group consisting of succinic acid, gluconic acid, alanine, glycine, valine, histidine, maltitol, and mannitol or at least one compound of the substance. A dry state of the reagent and deliquescence can be improved.

Подробнее
Номер записи: 16
03-05-2012 дата публикации

Method for predicting weight gain associated with a pharmaceutical therapy

Номер: US20120108947A1
Автор: Jennifer Kay Leohr
Принадлежит: Eli Lilly and Co

Methods for using TRL V6 as a biomarker for the risk of weight gain associated with treatment of a patient with a pharmaceutical agent, as for example, olanzapine.

Подробнее
Номер записи: 17
10-05-2012 дата публикации

Molecular flux rates through critical pathways measured by stable isotope labeling in vivo, as biomarkers of drug action and disease activity

Номер: US20120115127A1
Автор: Marc K. Hellerstein
Принадлежит: UNIVERSITY OF CALIFORNIA

The methods described herein enable the evaluation of compounds on subjects to assess their therapeutic efficacy or toxic effects. The target of analysis is the underlying biochemical process or processes (i.e., metabolic process) thought to be involved in disease pathogenesis. Molecular flux rates within the one or more biochemical processes serve as biomarkers and are quantitated and compared with the molecular flux rates (i.e., biomarker) from control subjects (i.e., subjects not exposed to the compounds). Any change in the biomarker in the subject relative to the biomarker in the control subject provides information to evaluate therapeutic efficacy of an administered drug or a toxic effect and to develop the compound further if desired. In one aspect of the invention, stable isotope-labeled substrate molecules are administered to a subject and the label is incorporated into targeted molecules in a manner that reveals molecular flux rates through metabolic pathways of interest.

Подробнее
Номер записи: 18
10-05-2012 дата публикации

Hydroxycholesterol immunoassay

Номер: US20120115169A1
Автор: James J. Donegan, Jeffrey Kroll Adams, Michael C. Mullenix, Robert Elliot Zipkin, Wayne Forrest Patton
Принадлежит: Enzo Life Sciences Inc

Provided is a derivative of 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Also provided is a protein conjugated to the above derivative. Further provided is an antibody composition comprising antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Additionally, a method of making antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Also, a method of assaying for 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Additionally provided is a kit for detecting 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. A method of detecting an enzyme or enzymes utilized in phase II drug metabolism is also provided. Also, a method of detecting an enzyme that synthesizes 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Further provided is a method of evaluating progression of multiple sclerosis in a patient. Also provided is a method of determining whether a treatment for multiple sclerosis in a patient is effective. Further, a method of evaluating progression of Huntington's disease in a patient is provided. Additionally provided is a method of determining whether a treatment for Huntington's disease in a patient is effective.

Подробнее
Номер записи: 19
17-05-2012 дата публикации

Method Of Identifying Compounds That Inhibit Fertilization

Номер: US20120122244A1
Автор: Chizuru Ito, Keiichi Yoshida, Kenji Yamatoya, Kiyotaka Toshimori
Принадлежит: Chiba University NUC

A method of identifying compounds that inhibit fertilization is provided. The method can include selecting compounds that bind to equatorin protein. Two types of equatorin protein, a long form and a short form, can be present in the testis. The amino acid sequence of mouse equatorin from positions 101 to 146 including the 138th O-glycosylated threonine residue contains an epitope recognized by anti-equatorin antibody MN9 that has an effect of inhibiting fertilization. In addition, the MN9 antibody also binds to human sperm. Compounds that bind to the epitope can inhibit fertilization. Both forms of mouse equatorin can be used as well as human equatorin to identify compounds that inhibit fertilization.

Подробнее
Номер записи: 20
17-05-2012 дата публикации

Alloyed metal colloid

Номер: US20120122245A1
Автор: Masatoshi Watabe, Suguru Akamatsu, Tetsuya Oda
Принадлежит: Kogakuin University, Otsuka Pharmaceutical Co Ltd

Provided is a metal colloid having higher visibility and higher sensitivity than a gold colloid and a Au-core Pt-shell composite colloid and suitable as a labeling agent for use in a test such as an immunoassay. An alloyed Au/Pt composite colloid formed by mixing a gold salt and a platinum salt with at least one reducing agent selected from the group consisting of an amino acid and a derivative thereof, an oligopeptide and a derivative thereof, and an amino sugar in the presence of an alkali, thereby reducing the gold salt and platinum salt.

Подробнее
Номер записи: 21
24-05-2012 дата публикации

Immunomodulation of Functional T Cell Assays for Diagnosis of Infectious or Autoimmune Disorders

Номер: US20120129197A1
Автор: Niaz Banaei
Принадлежит: Leland Stanford Junior University

Improved assays for detecting the presence of a specific cell-mediated immune response in an individual are provided, where a sample comprising T cells and other cells of the immune system, usually a blood sample or derivative thereof, is contacted with test antigen(s) of interest in the presence of a pattern recognition receptor (PRR) agonist. The sample is incubated for a period of time sufficient to activate effector T cells; and release of immune effector molecule(s) is then detected. In some embodiments, the PRR is an agonist of a toll-like receptor (TLR) expressed by mature antigen presenting cells, including without limitation agonists TLR3 and TLR7, such as LPS, poly I:C, imiquimod, etc.

Подробнее
Номер записи: 22
14-06-2012 дата публикации

Methods for assessing atherogenesis by determining oxidized phospholipid to apolipoprotein b ratios

Номер: US20120149596A1
Автор: Joseph L. Witztum, Sotirios Tsimikas
Принадлежит: UNIVERSITY OF CALIFORNIA

The present invention relates to the analysis of oxidized phospholipids (OxPL) on apolipoprotein B-100 in patients at high risk or with documented coronary artery disease (CAD) or acute coronary syndromes (ACS) such as unstable angina and acute myocardial infarction or suspected of being at risk for ACS. Such methods are useful for diagnostic purposes and for monitoring the effects of dietary interventions or with drugs such as statins. More particularly, the present invention relates to methods for determining OxPL/apoB ratios as indices of atherosclerosis regression and plaque stability.

Подробнее
Номер записи: 23
28-06-2012 дата публикации

Aspirin assay

Номер: US20120164756A1
Автор: Elouard Benchikh, Ivan Robert Mcconnell, Paul John Innocenzi, Philip Andrew Lowry, Stephen Peter Fitzgerald
Принадлежит: Randox Laboratories Ltd

The invention describes a method for monitoring and detecting non-therapeutic, therapeutic and toxic concentrations of aspirin in individuals which uses the urinary salicylic acid to salicyluric acid ratio.

Подробнее
Номер записи: 24
05-07-2012 дата публикации

Combination of spla2 activity and oxpl/apob cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event

Номер: US20120171705A1
Автор: Alain Tedgui, Joseph Witztum, Sotirios Tsimikas, Ziad Mallat
Принадлежит: Institut National de la Sante et de la Recherche Medicale INSERM, Universite Paris Diderot Paris 7, UNIVERSITY OF CALIFORNIA

The use of a combination of sPLA2 activity and OxPL/apoB cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event or for the monitoring of a cardiovascular disease.

Подробнее
Номер записи: 25
12-07-2012 дата публикации

Biomarkers and methods for detecting alzheimer's disease

Номер: US20120178637A1
Автор: David Witte, Jeffrey F. Waring, Melanie Joy Patterson, Viswanath Devanarayan
Принадлежит: ABBOTT LABORATORIES

Methods for classifying a test sample as indicative of Alzheimer's disease use protein and peptide biomarkers that are differentially expressed in the cerebral spinal fluid (CSF) of subjects with Alzheimer's disease relative to age-matched controls. The methods also use protein and peptide signatures indicative of Alzheimer's disease. Microarrays and kits for detecting the protein and peptide biomarkers in CSF samples can be used to classify Alzheimer's disease state from test samples.

Подробнее
Номер записи: 26
26-07-2012 дата публикации

Method for a rational cell culturing process

Номер: US20120190005A1
Автор: Jochen Schaub, Torsten Schulz
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Biopharmaceutical process development with recombinant protein producing mammalian cells has realized a tremendous increase in both productivity and product yields in the past years. These achievements can be mainly attributed to the advancements in cell line development, media, and process optimization. Only recently, genome-scale technologies enable a system-level analysis to elucidate the complex biomolecular basis of protein production in mammalian cells promising an increased process understanding and the deduction of knowledge-based approaches for further process optimization. The present invention describes a method for a rational cell culturing process using such a knowledge-based approach.

Подробнее
Номер записи: 27
02-08-2012 дата публикации

Synaptotagmin and collapsin response mediator protein as biomarkers for traumatic brain injury

Номер: US20120196307A1
Автор: Andrew K. Ottens, Firas H. Kobaissy, Ka-Wang (Kevin) Wang, Ming Chen Liu, Monika Oli, Ronald L. Hayes, Zhiqun Zhang
Принадлежит: Banyan Biomarkers Inc, University of Florida Research Foundation Inc

Collapsin response mediator proteins (CRMPs) decreased in tissue and increased in biological samples after neural injury from traumatic brain injury (TBI). Significant decreases of CRMP1, CRMP2, CRMP4 and CRMP5 were accompanied by the appearance of distinct 58 kDa (CRMP-2) or 55 kDa (CRMP-4) breakdown products from proteolytic cleavage by calpain. Synaptotagmin breakdown products were also associated with TBI and could be detected along with intact protein in human cerebral spinal fluid (biological samples). Both biomarkers were detected in human biofluid and related to recovery from traumatic brain injury.

Подробнее
Номер записи: 28
09-08-2012 дата публикации

Serum-based biomarkers of pancreatic cancer and uses thereof for disease detection and diagnosis

Номер: US20120202188A1
Автор: Elodie Pastural, Shawn Ritchie
Принадлежит: Phenomenome Discoveries Inc

Biomarkers of pancreatic cancer are described, as well as methods using these compounds for detecting pancreatic cancer. The methods can be used to diagnose a patient's health state, or change in health state, or for diagnosing risk of developing or the presence of pancreatic cancer. The method comprises analyzing a sample from a patient to obtain quantifying data for one or more than one of the metabolite markers; comparing the quantifying data to corresponding data obtained for one or more than one reference sample to identify abnormalities in the level of the metabolite marker(s) in the sample; and making a diagnosis if an abnormality is observed. Standards and kits for carrying out the method are also described.

Подробнее
Номер записи: 29
09-08-2012 дата публикации

Synergistic biomarker assay of neurological condition using s-100b

Номер: US20120202231A1
Автор: Jackson Streeter, Kevin Ka-Wang Wang, Ronald L. Hayes
Принадлежит: Hayes Ronald L, Jackson Streeter, Kevin Ka-Wang Wang

Processes and assays are provided for detecting and determining the magnitude of traumatic brain injury such as that from impact or percussive trauma or stroke. The inventive assays and processes recognize a synergistic correlation between detection of S-IOOb and one or more other injury specific biomarkers.

Подробнее
Номер записи: 30
16-08-2012 дата публикации

METHOD FOR ASSAYING CHOLESTEROL IN ApoE-CONTAINING HDL

Номер: US20120208219A1
Автор: Hitoshi Chiba, Yasuki Itoh
Принадлежит: Denka Seiken Co Ltd, Hokkaido University NUC

This invention provides a method for separately or simultaneously quantifying cholesterol in a total amount of HDL-C, cholesterol in an HDL subfraction of apoE-containing HDL-C, and cholesterol in an HDL subfraction of apoE-deficient HDL-C. The method comprises enzymatically and separately quantifying cholesterol in apoE-containing HDL and cholesterol in apoE-deficient HDL by adding a surfactant selected from the group consisting of a surfactant with an apoE-containing HDL response rate/apoE-deficient HDL response rate ratio of 0.7 to less than 1.3, a surfactant with an apoE-containing HDL response rate/apoE-deficient HDL response rate ratio of less than 0.7, and a surfactant with an apoE-containing HDL response rate/apoE-deficient HDL response rate ratio of 1.3 or more to a test sample, allowing cholesterol esterase and cholesterol oxidase to react therewith, and quantifying the hydrogen peroxide generated.

Подробнее
Номер записи: 31
23-08-2012 дата публикации

Doxorubicin immunoassay

Номер: US20120214184A1
Автор: Jodi Blake Courtney, Salvatore J. Salamone, Shu He
Принадлежит: Individual

Novel conjugates of doxorubicin and novel doxorubicin immunogens derived from the 13 and 14 positions of doxorubicin and antibodies generated by these doxorubicin linked immunogens all of which are useful in immunoassays for the quantification and monitoring of doxorubicin in biological fluids.

Подробнее
Номер записи: 32
30-08-2012 дата публикации

Galactose-Alpha-1,3-Galactose-Macromolecule Conjugates And Methods Employing Same

Номер: US20120219975A1
Автор: Ramon Evangelista, Utpal Banik, Wei-Xing Gan
Принадлежит: Siemens Healthcare Diagnostics Inc

Methods and reagents are disclosed for conducting assays for IgE. Embodiments of the present reagents comprise a conjugate of a macromolecule and a compound comprising a galactose-α-1,3-galactose epitope. Embodiments of the present methods are directed to determining the presence and/or amount of an IgE specific for a galactose-α-1,3-galactose epitope in a sample. A combination is provided in a medium, which comprises the sample and a reagent for determining the presence and/or amount of an IgE specific for a galactose-α-1,3-galactose epitope in a sample wherein the reagent comprises a conjugate of a macromolecule and a compound comprising a galactose-α-1,3-galactose epitope. The combination is subjected to conditions for binding of the IgE to the reagent to form a complex. The presence and/or amount of the complex are detected and the amount of the complex is related to the presence and/or amount of IgE in the sample.

Подробнее
Номер записи: 33
06-09-2012 дата публикации

Method for predicting autism spectrum disorders by cannabinoid and cannabinoid receptor expression

Номер: US20120225015A1
Автор: Georgianna G. Gould, Mauris N. DeSilva, Stephen T. Schultz
Принадлежит: Desilva Mauris N, Gould Georgianna G, Schultz Stephen T

The inventive method relates to a method for the determination of susceptibility or diagnosis of autism or autism spectrum disorders. Diagnosis or determination of susceptibility determinations are predicated on quantitative analysis of endocannibinoid levels or endocannibinoid receptor expression.

Подробнее
Номер записи: 34
13-09-2012 дата публикации

Protein arrays and uses thereof

Номер: US20120231969A1
Автор: Donghui Ma, Wei-Wu He, Youmin Shu, Zairen Sun
Принадлежит: Origene Technologies Inc

Illustrative embodiments herein disclosed relate to protein arrays, methods for making the arrays and methods for using them, among others. In some embodiments known proteins representing at least 50% of the loci in the human genome are arrayed in known positions on a support. In some embodiments arrays are made of proteins purified from cell lysates by affinity binding to the support. In some embodiments protein arrays are used to decode the binding specificity of antibodies. In some embodiments protein arrays are used to diagnose auto-immune disorders. Many other embodiments and general features are disclosed.

Подробнее
Номер записи: 35
20-09-2012 дата публикации

Methods to Identify Modulators

Номер: US20120237953A1
Автор: Christopher Todd Simons, Ioana Maria Ungureanu, Jay Patrick Slack, Jenny Ellen Evans Pennimpede, Kimberly Gray, Nicole Erna Irene Brune
Принадлежит: Givaudan SA

Sucralose-binding TAS2R bitter taste receptors have been identified. Novel methods to identify modulators and in particular inhibitors to the bitter taste of sucralose, and an inhibitor, are provided.

Подробнее
Номер записи: 36
20-09-2012 дата публикации

Rantes levels as a diagnostic and therapeutic for acute graft versus host disease

Номер: US20120238460A1
Автор: Eugenie Suter, Eva Guinan, Ofer Levy
Принадлежит: Childrens Medical Center Corp, Dana Farber Cancer Institute Inc

Disclosed herein are methods for determining the likelihood of a subject to develop Acute graft versus host disease (aGVHD) upon receiving myeloablative allogeneic hematopoietic stem cell transplantation (HSCT). One such method comprises assaying for baseline plasma concentration of RANTES in a sample obtained from the subject, and comparing the baseline plasma concentration of RANTES to a predetermined level. The method may further comprise assaying for day 7 plasma concentration of RANTES in sample obtained from the subject, and comparing the day 7 plasma concentration of RANTES to a predetermined level. Another such method comprises assaying for day 7 plasma concentration of RANTES in a sample obtained from the subject, and comparing the day 7 plasma concentration of RANTES to a predetermined level. Another such method comprises assaying for donor plasma concentration of RANTES in a sample obtained from a donor of the hemtopoietic stem cells, and comparing the donor plasma concentration of RANTES to a predetermined level, wherein a donor plasma concentration of RANTES less than the predetermined level indicates a likelihood of the subject to develop aGVHD upon receiving myeloablative allogeneic HSCT from that donor. Other methods include assaying for day 0, or for day 7, plasma concentration of MCP-1 in a sample obtained from the subject, and comparing the day 0 or day 7, plasma concentration of MCP-1 to a predetermined level.

Подробнее
Номер записи: 37
04-10-2012 дата публикации

Real time multipoint assay for optimizing performance

Номер: US20120252000A1
Автор: Barb Ariel Cohen
Принадлежит: Barb Ariel Cohen

Described herein are methods of optimizing the performance of a mammalian semen sample with respect to outcomes such as fertility, using a multipoint assay to determine an optimum time point for preparing the semen sample for use in insemination. The multipoint assay is based upon a kinetic model of biomarker expression during sperm capacitation relative to the outcome of interest.

Подробнее
Номер записи: 38
04-10-2012 дата публикации

Novel biomarkers of disease histopathology

Номер: US20120252688A1
Автор: Diego Clemente López, Fernando De Castro Soubriet, Francisco Javier ARENZANA SANAGÉRICO, maría Ortega Muñoz
Принадлежит: Fundacion Hospital Nacional de Paraplejicos Para la Investigacion Y la Integracion (FUHNPAIIN)

Use of FGF-2 and Anosmin-1 proteins to predict the histopathology of the lesions of a subject with a demyelinating disease of the central nervous system (CNS) by detecting the amount of such proteins in a sample of isolated biological fluid. Furthermore, the present invention relates to a method for the understanding of the histopathological features of the lesions of a subject with a CNS demyelinating disease a kit to carry out this method. Preferably, the CNS demyelinating disease is multiple sclerosis, and the biological fluid is cerebrospinal fluid (CSF).

Подробнее
Номер записи: 39
11-10-2012 дата публикации

Transdermal systems, devices, and methods to optically analyze an analyte

Номер: US20120258467A1
Автор: Paul Ripley, Swetha Chinnayelka
Принадлежит: Bayer HealthCare LLC

The invention provides transdermal optical analysis systems, test sensors, methods, and kits for determining the presence and/or concentration of at least one analyte in a fluid sample. The system includes a transdermal test sensor including an aqueous material including at least one analyte selective reagent and at least one optically active moiety. The optical system preferably uses fluorescent spectroscopy to correlate fluorescent emission or adsorption from a dye with the analyte concentration of the sample. An optical light source and/or detector may be housed with the aqueous material in a housing or external to the housing of the aqueous material.

Подробнее
Номер записи: 40
18-10-2012 дата публикации

Method for quantifying biomolecules

Номер: US20120264154A1
Автор: Francesca Forner, Jacek R. Wisniewski, Jürgen Cox, Matthias Mann, Tamar Geiger
Принадлежит: Max Planck Gesellschaft zur Foerderung der Wissenschaften eV

The present invention relates to a method that allows comprehensive quantitation of one or a plurality biomolecules, including the entire complement of biomolecules in a sample by comparing their quantity to the quantity of reference biomolecules in a standard mixture obtained via extraction from at least two different cell populations. The invention further relates to said standard mixture itself, its preparation and use.

Подробнее
Номер записи: 41
01-11-2012 дата публикации

Method for Specific Cleavage of N-CA Bond in Peptide Main Chain

Номер: US20120276643A1
Автор: Mitsuo Takayama
Принадлежит: YOKOHAMA CITY UNIVERSITY

The present invention provides a peptide degradation reagent with the following characteristics: 1) it has no marked toxicity such as carcinogenicity, 2) it does not produce metastable peaks resulting from excessive degradation property, 3) it does not produce multiply-charged ion peaks which are interference peaks, and 4) it can secure separation and sharpness of peaks. The present invention also provides a method for specifically cleaving N—Cα bonds on a peptide backbone using the above-described reagent, and a method of determining the amino acid sequence of a peptide utilizing this specific cleavage. A method for specifically cleaving N—Cα bonds on the backbone of a peptide, comprising irradiating the peptide with laser light in the presence of 5-amino salicylic acid. A method for determining the amino acid sequence of a peptide, comprising irradiating the peptide with laser light in the presence of 5-amino salicylic acid to thereby specifically cleave N—Cα bonds on the peptide backbone. A reagent for specifically cleaving N—Cα bonds on a peptide backbone; a hydrogen radical-releasing reagent; a matrix reagent for MALDI-ISD; a matrix for MALDI-ISD; a peptide ionization reagent for MALDI-ISD; and a kit for MALDI-ISD.

Подробнее
Номер записи: 42
15-11-2012 дата публикации

Diagnostic Test For The Detection Of A Molecule Or Drug In Whole Blood

Номер: US20120288875A1
Автор: Frank C. Grenier, Hina N. Syed, Ryan F. Workman, Salman Ali
Принадлежит: ABBOTT LABORATORIES

The invention provides methods of preparing a test sample for use in an assay for detecting an analyte bound by an intracellular ligand. The methods typically involve contacting the test sample with an assay reagent comprising: a lysis reagent; and a protease that has proteolytic activity for said intracellular ligand; to form a mixture compatible for use in an immunoassay without subsequent extraction steps. Other aspects of the invention include related immunoassays and test kits.

Подробнее
Номер записи: 43
22-11-2012 дата публикации

Compound capable of binding to naturally occurring denatured protein, and method for screening for the compound

Номер: US20120296067A1
Автор: Hiroyuki Kouji
Принадлежит: Prism BioLab Co Ltd

Screening for low molecular weight compounds that regulate protein-protein interactions of a large number of proteins, including transcription factors, that have disordered sequences has been performed, but it has been almost impossible to obtain low molecular weight compounds having sufficient activity. The present inventors found that, regarding screening for a protein that regulates an interaction between an intrinsically disordered protein and a partner protein, carrying out screening while focusing on an disordered sequence, and selecting a candidate compound from peptidomimetic compounds that have a peptidomimetic backbone and have a peptide side chain or a side chain similar thereto enable a compound that regulates the activity of an intrinsically disordered protein to be efficiently selected, and the present inventors accomplished the present invention.

Подробнее
Номер записи: 44
29-11-2012 дата публикации

Mass spectrometry method

Номер: US20120301968A1
Автор: Hiroyuki Hashimoto, Jumpei Naito, Manabu Komatsu, Shuya Satoh
Принадлежит: Canon Inc

The problem to be solved by the present invention is to provide a method for treating a polypeptide including a cysteine residue for enhancing the sensitivity of detection thereof in mass spectrometry using charged particles. A mass spectrometry method for a polypeptide including a cysteine residue is provided which includes treating the polypeptide including a cysteine residue with a cyanation agent, treating the cyanated polypeptide with a base, and then desorption ionizing the base-treated polypeptides using charged particles for mass spectrometry.

Подробнее
Номер записи: 45
06-12-2012 дата публикации

METHOD OF ANALYZING HUMAN sCD14-ST

Номер: US20120309025A1
Автор: Hiroyuki Yokoi, Yoshikazu Okamura
Принадлежит: Mochida Pharmaceutical Co Ltd

An analysis method capable of accurately measuring human sCD14-ST when using a whole blood sample is provided. In the analysis method, human sCD14-ST in a whole blood sample is analyzed within 6 hours of the collection of the sample.

Подробнее
Номер записи: 46
20-12-2012 дата публикации

Biomarker for amyotrophic lateral sclerosis and diagnostic kit and method used thereof

Номер: US20120322082A1
Автор: Chi-Shin Hwang, Hao-Teng Chang, Margaret Dah-Tsyr Chang
Принадлежит: CHINA MEDICAL UNIVERSITY, National Tsing Hua University NTHU

A diagnostic marker for determining of a patient with amyotrophic lateral sclerosis (ALS), comprising an autoantibody against a human protein HMGB1 is described. A diagnostic kit for determining of a patient with ALS, comprising: (a) an HMGB1 protein; and (b) an HMGB1 antibody standard is also presented. A method of determining ALS in a subject, comprising the steps: (a) detecting autoantibody against HMGB1 in a biological sample taken from the subject and normal control individuals; and (b) statistically comparing concentrations of the autoantibody against HMGB1 in the subject with that of the normal control individuals obtained from step (a); wherein a higher concentration of the autoantibody against HMGB1 in the subject than a cut-off concentration indicates the subject suffers from ALS is further described.

Подробнее
Номер записи: 47
03-01-2013 дата публикации

Systems and methods of discriminating control solution from a physiological sample

Номер: US20130001103A1
Автор: Alastair M. Hodges, Ronald C. Chatelier
Принадлежит: Lifescan Inc

Methods for distinguishing between an aqueous non-blood sample (e.g., a control solution) and a blood sample. In one aspect, the methods include using a test strip in which multiple current transients are measured by a meter electrically connected to an electrochemical test strip. The current transients are used to determine if a sample is a blood sample or an aqueous non-blood sample based on at least two characteristics (e.g., amount of interferent present and reaction kinetics). The method can also include calculating a discrimination criteria based upon at least two characteristics. Various aspects of a system for distinguishing between blood samples and an aqueous non-blood sample are also provided herein.

Подробнее
Номер записи: 48
03-01-2013 дата публикации

Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Номер: US20130005601A1
Автор: James Patrick Kampf, Jeff Gray, Joseph Anderberg, Kevin Nakamura, Paul Mcpherson
Принадлежит: Astute Medical Inc

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Endothelin-1, Somatotropin, and Interleukin-13 as diagnostic and prognostic biomarkers in renal injuries.

Подробнее
Номер записи: 49
10-01-2013 дата публикации

Methods for detecting insulin autoantibody

Номер: US20130011860A1
Автор: George S. Eisenbarth, Liping Yu
Принадлежит: University of Colorado

The present invention provides methods for detecting insulin autoantibody. Such methods can be used, for example, to predict susceptibility of and/or diagnose the presence of Type 1 diabetes in a subject. Some aspects of the invention also provide kits adapted for use in such methods. In particular, some aspects of the invention use proinsulin to detect the presence of insulin autoantibody.

Подробнее
Номер записи: 50
17-01-2013 дата публикации

COMBINATION OF sPLA2 TYPE IIA MASS AND OXPL/APOB CARDIOVASCULAR RISK FACTORS FOR THE DIAGNOSIS/PROGNOSIS OF A CARDIOVASCULAR DISEASE/EVENT

Номер: US20130017557A1
Автор: Alain Tedgui, Joseph Witztum, Sotirios Tsimikas, Ziad Mallat
Принадлежит: BIO-SYNECTICS Inc, Institut National de la Sante et de la Recherche Medicale INSERM, JW Pharmaceutical Corp, UNIVERSITY OF CALIFORNIA

The present invention related to a method of identifying a subject having or at risk of having or developing a cardiovascular disease and/or a cardiovascular event, comprising: —measuring, in a sample obtained from said subject, at least two cardiovascular risk factors: a) sPLA2 type HA mass and b) oxidized phospholipids on apolipoprotein B-IOO particles (OxPL/apoB), —combining said measurements, the combined value of sPLA2 type HA mass and OxPL/apoB being indicative of having or a risk of having or developing a cardiovascular disease and/or cardiovascular event.

Подробнее
Номер записи: 51
31-01-2013 дата публикации

Method for avoiding influence of endogenous lipoprotein and reagent

Номер: US20130029429A1
Автор: Takayuki Abe, Tetsuya Ota, Yuki Takahashi
Принадлежит: Sekisui Medical Co Ltd

To identify the aforementioned interference component present in serum or plasma, to thereby provide means for avoiding any interference effect caused by the component.

Подробнее
Номер записи: 52
07-02-2013 дата публикации

Method for the extraction and detection of fat-soluble components from biological materials

Номер: US20130034873A1
Автор: Florian J. Schweigert
Принадлежит: DSM IP ASSETS BV

The present invention relates to a method for the analysis of fat-soluble components, in particular dyes, from biological materials, in particular lipid rich foodstuffs, having an enrichment of the components and subsequent analysis. The method comprises a combination of extraction and separation steps and a subsequent analysis step. The invention further relates to an analytical kit and analytical equipment for carrying out the method. The method according to the invention is composed of a plurality of steps. The critical steps which are essential and characterize the invention are: 1. Pre-treatment of the sample to remove lipids. 2. Extracting the dyes into an extraction mixture by a specific solvent or solvent mixture. 3. Destruction of the oxidative sensible ingredients such as carotenoids prior to the final detection and quantification by eye or by optical enhancement.

Подробнее
Номер записи: 53
07-02-2013 дата публикации

Mobile remote alcohol monotoring device

Номер: US20130035602A1
Автор: Gil Gemer
Принадлежит: 3M Innovative Properties Co

A monitoring apparatus including an ethanol level sensor; an ECG sensor for generating an ECG circuit for sampling an electrical activity of a heart of a monitored person being monitored; and an air inlet component connected to an air flow sensor; wherein a first electrode is attached to the breath inlet component and wherein the ECG circuit is generated when a monitored person is in electrical contact with the first electrode and the second electrode of the ECG.

Подробнее
Номер записи: 54
28-02-2013 дата публикации

Genes differentially expressed by cumulus cells and assays using same to identify pregnancy competent oocytes

Номер: US20130053261A1
Автор: Amy E. Iager, Hasan H. Otu, Jose B. Cibelli
Принадлежит: GEMA DIAGNOSTICS Inc

A genetic means of identifying “pregnancy competent” oocytes is provided. The means comprises detecting the level of expression of one or more genes that are expressed at characteristic levels (upregulated or downregulated) in cumulus cells derived from pregnancy competent oocytes. This characteristic gene expression level, or pattern referred to herein as the “pregnancy signature”, also can be used to identify subjects with under-lying conditions that impair or prevent the development of a viable pregnancy, e.g., pre-menopausal condition, other hormonal dysfunction, ovarian dysfunction, ovarian cyst, cancer or other cell proliferation disorder, autoimmune disease and the like. In preferred embodiments the pregnancy signature will comprise one or more of AB-CA6, NCAM1, OLFML3, PTPRA, SDF4, GPR137B, DDIT4, DUSP1, GPR137B, IDUA, KCTD5, NDNL2, SLC26A3, and TERF2IP.

Подробнее
Номер записи: 55
14-03-2013 дата публикации

Disease Diagnosis Method, Marker Screening Method and Marker Using TOF-SIMS

Номер: US20130065266A1
Автор: Byong Chul Yoo, Dae Won Moon, In Hoo Kim, Tae Geol Lee
Принадлежит: Korea Research Institute of Standards and Science KRISS

The present invention relates to a disease diagnosis method, a marker screening method, and a marker using a time-of-flight secondary ion mass spectrometry (TOF-SIMS), and more particularly, to a large intestine cancer diagnosis method, a large intestine cancer marker screening method, and a large intestine cancer marker using a time-of-flight secondary ion mass spectrometry (TOF-SIMS). Specifically, the present invention provides a method diagnosing a disease using a pattern of secondary ion mass (m/z) peaks of biological samples measured using a time-of-flight secondary ion mass spectrometry (TOF-SIMS) as a marker, a marker screening method being a reference judging an existence or non-existence of a disease, and a marker configured of specific secondary ion mass peaks.

Подробнее
Номер записи: 56
21-03-2013 дата публикации

Theranostic and diagnostic methods using sparc and hsp90

Номер: US20130072389A1
Автор: Ramin Akhavan, Robert J. Penny
Принадлежит: Caris Life Sciences Inc

Provided herein are methods and systems of molecular profiling of diseases, such as cancer. The molecular profiling can be used to provide a diagnosis, prognosis, or theranosis for the disease, such as identifying a candidate treatment. The methods can detect overexpression of SPARC and HSP90. The cancer can be, e.g., a renal cell carcinoma or an interdigitating dendritic cell sarcoma.

Подробнее
Номер записи: 57
28-03-2013 дата публикации

BIOMARKERS AND METHODS FOR DETECTING AND TREATING SPINAL AND JOINT PAIN

Номер: US20130078246A1
Автор: Bowser Robert, Hanna Lewis S., Scuderi Gaetano J.
Принадлежит:

Biomarkers, including isolated fibronectin-aggrecan complexes that correlate with spinal or joint pain and inflammation, and methods for their detection are provided. Also provided are methods for identifying treatment sites in the spine or joint for treatment of pain and inflammation by detecting the presence of, or increased levels of, fibronectin-aggrecan complexes. Methods for treating spinal or joint pain and inflammation are also provided. 1. A method for identifying a treatment site in a subject , comprising:a) obtaining one or more biological samples from one or more sites in the subject; and,b) selecting for treatment a target site that yields, in the one or more biological samples from the site, one or more fibronectin/aggrecan complexes comprising fibronectin or a fragment thereof and aggrecan or a fragment thereof.2. The method of wherein one or more fibronectin/aggrecan complexes comprises G1 claim 1 , IGD claim 1 , G2 claim 1 , KS claim 1 , CS 1 claim 1 , CS2 or G3 domains of aggrecan or fragments thereof.3. The method of claim 1 , wherein the one or more biological samples are obtained by lavage claim 1 , aspiration claim 1 , injection-aspiration claim 1 , biopsy claim 1 , fine-needle aspiration biopsy claim 1 , core biopsy claim 1 , endoscopic or open biopsy.4. The method of claim 1 , wherein one or more biological samples is obtained from a space in the spine selected from the group of the epidural claim 1 , intradiscal claim 1 , extradiscal claim 1 , or facet-joint intra-articular spaces.5. The method of claim 1 , wherein one or more biological samples is obtained from a class of joints selected from the synovial claim 1 , diarthrodial claim 1 , amphiarthrodial claim 1 , or synarthrodial joints.6. The method of claim 5 , wherein the joint is selected from the group of shoulder claim 5 , elbow claim 5 , carpal claim 5 , metacarpal claim 5 , phalangeal claim 5 , acromioclavicular claim 5 , sternoclavicular claim 5 , scapular claim 5 , costal claim 5 ...

Подробнее
Номер записи: 58
28-03-2013 дата публикации

FC RECEPTOR BINDING PROTEINS

Номер: US20130078262A1
Автор: Bitonti Alan J., Dumont Jennifer, Ladner Robert Charles, Liu Liming, McDonnell Kevin, Muruganandam Arumugam, Sato Aaron, Stattel James, TenHoor Christopher, Viswanathan Malini, Wood Clive
Принадлежит: DYAX CORP.

This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders. 1. An isolated antibody comprising a heavy chain (HC) immunoglobulin variable domain sequence and a light chain (LC) immunoglobulin variable domain sequence , (a) a human CDR or human framework region;', '(b) the LC immunoglobulin variable domain sequence comprises one or more CDRs that are at least 85% identical to a CDR of a LC variable domain of M0171-A03, M0171-A01, M0159-A07, M0161-B04, M0090-F11 or DX2500;', '(c) the HC immunoglobulin variable domain sequence comprises one or more CDRs that are at least 85% identical to a CDR of a HC variable domain of M0171-A03, M0171-A01, M0159-A07, M0161-B04, M0090-F11 or DX2500;', '(d) the LC immunoglobulin variable domain sequence is at least 85% identical to a LC variable domain of M0171-A03, M0171-A01, M0159-A07, M0161-B04, M0090-F11 or DX2500;', '(e) the HC immunoglobulin variable domain sequence is at least 85% identical to a HC variable domain of M0171-A03, M0171-A01, M0159-A07, M0161-B04 M0090-F11 or DX2500; and', '(f) the antibody binds an epitope that overlaps with an epitope bound by M0171-A03, M0171-A01, M0159-A07, M0161-B04, M0090-F11 or DX2500., 'wherein the heavy chain and light chain immunoglobulin variable domain sequences form an antigen binding site that binds to human FcRn; and wherein the antibody includes one or more of the following characteristics2. An isolated antibody that is at least 85% identical to an antibody selected from the group consisting of M0171-A03 , M0171-A01 , M0159-A07 , M0161-B04 , M0090-F11 and DX2500.3. An isolated antibody , wherein the antibody is selected from the group consisting of M0171-A03 , M0171-A01 , M0159-A07 , M0161-B04 , M0090-F11 and DX2504.4. An isolated antibody comprising the CDRs of M0161-B04.5. An isolated antibody that is ...

Подробнее
Номер записи: 59
28-03-2013 дата публикации

METHOD FOR QUANTITATIVELY DETERMINING LDL CHOLESTEROLS

Номер: US20130078659A1
Автор: Hino Koichi, Manabe Mitsuhisa, Nakamura Mitsuhiro, Nakanishi Kazuo
Принадлежит:

A method for quantitatively determining LDL cholesterol, including the steps of adding to serum a surfactant selected from among polyoxyethylenealkylene phenyl ethers and polyoxyethylenealkylene tribenzylphenyl ethers and a cholesterol-assaying enzyme reagent so as to preferentially react cholestrols in high density- and very low density-cholesterols among lipoproteins, and subsequently determining the amount of cholesterol that reacts thereafter. This method can eliminate the necessity for pretreatments such as centrifugation and electrophoresis, enables the quantitative determination to be conducted in an efficient, simple manner, and can be applied to various automatic analyzers. 1. A method for quantitatively determining low density lipoprotein cholesterol , comprising the steps of adding to serum a surfactant selected from among polyoxyethylenealkylene phenyl ethers and polyoxyethylenealkylene tribenzylphenyl ethers and a cholesterol-assaying enzyme reagent , to thereby induce preferential reactions of cholesterols in high density- and very low density-lipoproteins among lipoproteins , and subsequently determining the amount of cholesterol which reacts thereafter.2. A method for quantitatively determining low density lipoprotein cholesterol , characterized by comprising the steps of adding to serum a surfactant selected from among polyoxyethylenealkylene phenyl ethers and polyoxyethylenealkylene tribenzylphenyl ethers , a substance exhibiting stronger bonding affinity to very low density lipoprotein than to low density lipoprotein , and a cholesterol-assaying enzyme reagent , to thereby induce preferential reactions cholesterols in high density- and very low density-lipoproteins among lipoproteins , and subsequently , determining the amount of cholesterol which reacts thereafter.3. The method for quantitatively determining low “density lipoprotein cholesterol according to claim 2 , wherein the substance exhibiting stronger bonding affinity to very ‘low density ...

Подробнее
Номер записи: 60
28-03-2013 дата публикации

Control Solution For Use In An Electrochemical System

Номер: US20130078724A1
Автор: Fu Hsiung Tsai, Henry C. Arndt, Huan-Ping Wu, Jing Lin, Nicole D. ELLIS
Принадлежит: Bayer HealthCare LLC

A method of distinguishing a control solution from a sample in an electrochemical test sensor is performed. The method includes adding a control marker to the control solution. The control solution includes the control marker and analyte. The test sensor includes working and counter electrodes, and a reagent. A potential is applied to the test sensor to oxidize the control marker and the analyte. The resulting electrical current is measured. A potential is applied to the test sensor lower than the other potential in which the potential is sufficient to oxidize the analyte and not the control marker. The resulting electrical current is measured. Determining whether a control solution or a sample is present based on the measured electrical currents. To increase the measured current, a salt may be added to the control solution in an amount sufficient to increase the electrical current by at least 5% as compared to a control solution in the absence of a salt.

Подробнее
Номер записи: 61
28-03-2013 дата публикации

Method Of Treating Acute Lung Injury Using Sphingosine 1 Phosphate Analogs Or Sphingosine 1 Phosphate Receptor Agonists

Номер: US20130079309A1
Автор: Joe G.N. Garcia, Steven M. Dudek
Принадлежит: University of Illinois

The invention provides methods for treating or reducing the risk of developing acute lung injury manifested by increased vascular permeability. Also provided are pharmaceutical compositions comprising an FTY720 analog or derivative and/or SEW 2871 for use in the disclosed methods. The invention also provides methods for treating or reducing the risk of developing acute lung injury resulting from dysregulation of ceramide/sphingolipid pathway, more specifically, acute lung injury resulting from radiation.

Подробнее
Номер записи: 62
04-04-2013 дата публикации

IGF-1R SPECIFIC ANTIBODIES USEFUL IN THE DETECTION AND DIAGNOSIS OF CELLULAR PROLIFERATIVE DISORDERS

Номер: US20130084243A1
Автор: Brooks David, Chastain Michael, CORVAIA Nathalie, GOETSCH Liliane, Zhang Zhi-Qiang
Принадлежит:

The present invention relates to mammalian antibodies, designated 12B1 and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), preferably human IGF-IR. Also included are chimeric, bispecific, derivatized, single chain antibodies derived from the antibodies disclosed herein. Nucleic acid molecules encoding the mammalian antibodies as well as methods of use thereof are also disclosed. Also included are pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for treatment and diagnosis of pathological hyperproliferative oncogenic disorders associated with expression of IGf-1R. 1. An antibody or an antigen-binding portion thereof that specifically binds insulin-like growth factor I receptor (IGF-IR) , comprising at least one light chain sequence and at least one heavy chain sequence , wherein said light chain comprises at least one complementarity determining region (CDR) selected from the group consisting of the amino acids sequences as set forth in SEQ ID NO. 1 , 2 , or 3 , or at least one CDR comprising an amino acid sequence having at least 80% identity with the sequence set forth in SEQ ID NO. 1 , 2 , or 3 , and wherein said heavy chain comprises at least one complementarity determining region (CDR) selected from the group consisting of the amino acids sequences as set forth in SEQ ID NO. 4 , 5 or 6 , or at least one CDR comprising an amino acid sequence having at least 80% identity after with the sequence set forth in SEQ ID NO. 4 , 5 or 6.2. The antigen-binding portion according to claim 1 , wherein said portion is selected from the group consisting of: a Fab fragment claim 1 , an F(ab′)fragment and an Fv fragment.3. The antibody according to claim 1 , wherein said light chain comprises the amino acid sequence as set forth in SEQ ID NO: 7 and said heavy chain comprises the amino acid sequence as set forth in SEQ ID NO:8.4. A monoclonal antibody that ...

Подробнее
Номер записи: 63
04-04-2013 дата публикации

DRUG SUSCEPTIBILITY USING RARE CELL DETECTION SYSTEM

Номер: US20130084579A1
Автор: Bresler Herbert S., Haubert Thomas D., Laudo John S., Taylor Kevin M.
Принадлежит: BATTELLE MEMORIAL INSTITUTE

Methods for determining the efficacy of a given drug for a specific patient with cancer in vitro prior to, or after, the initiation of treatment of the patient are disclosed. Blood from the cancer patient is separated into an assay test tube and a control test tube. The blood in the assay test tube is exposed to a cancer drug. The two test tubes are then visually examined and compared to determine the effect of the cancer drug on cancer cells, other rare cells in the blood, or on normal constituents of the blood of a cancer patient. 1. A method of testing for drug susceptibility in a cancer patient , comprising:{'b': 2320', '2330, 'obtaining a control test tube () and an assay test tube (), each test tube containing blood from the cancer patient;'}{'b': '2340', 'adding a drug to the assay test tube ();'}{'b': '2350', 'introducing a separator float into the assay test tube ();'}{'b': '2360', 'moving the float into alignment with the cancer cells to capture the cancer cells in an annular volume ();'}extracting the cancer cells from the annular volume;visually examining the cancer cells; and{'b': '2380', 'comparing the effect of the drug on cancer cells in the assay test tube to cancer cells in the control test tube ().'}2. The method of claim 1 , wherein the drug is a fluorescently labeled drug.3. The method of claim 1 , wherein a change in the shape of the cancer cells is compared between the assay test tube and the control test tube.42362. The method of claim 1 , further comprising staining the cancer cells () prior to visually examining the assay test tube.5. The method of claim 1 , wherein the visual examination is performed by detecting a quantity of fluorescence.62372. The method of claim 1 , further comprising visually examining the control test tube ().7. The method of claim 1 , wherein the movement of the float is performed by:centrifuging the assay test tube to move the float into alignment with the cancer cells; andreducing rotational speed to capture the ...

Подробнее
Номер записи: 64
04-04-2013 дата публикации

Method of Identifying Transmembrane Protein-Interacting Compounds

Номер: US20130084581A1
Автор: "ODowd Brian F.", George Susan R.
Принадлежит: Omeros Corporation

A method for screening compounds for their ability to interact with transmembrane proteins is provided. Also provided is a method for determining whether proteins such as transmembrane proteins are able to oligomerise. 1. A method for screening a candidate compound for its ability to interact with at least one transmembrane protein comprising:contacting a cell with a candidate compound wherein the cell is transfected with at least one nucleotide sequence encoding a protein comprising a transmembrane protein containing at least one nuclear localization sequence (NLS) and a detectable moiety and the encoded protein is expressed in the cell; and wherein the transmembrane protein exhibits basal agonist-independent translocation into the cell nucleus; anddetermining the distribution of the expressed protein in the cell by detecting the distribution of the detectable moiety in the cell;wherein retention of the detectable moiety at the cell membrane in cells contacted with the candidate compound, relative to control cells not contacted with the candidate compound, indicates interaction of the candidate compound with the transmembrane protein, and wherein the wild type transmembrane protein contains an NLS.2. The method of claim 1 , wherein the detectable moiety is a detectable peptide comprising an antigenic portion of the amino acid sequence of the transmembrane protein3. The method of claim 1 , wherein the nucleotide sequence encodes a fusion protein comprising a transmembrane protein containing at least one NLS and a detectable moiety.4. The method of claim 1 , wherein the NLS is selected from Table 1.5. The method of claim 1 , wherein the NLS is selected from the group consisting of KKFKR (SEQ ID NO:158) claim 1 , PKKKRKV (SEQ ID NO:154) and AFSAKKFKR (SEQ ID NO:159).6. The method of claim 1 , wherein the detectable moiety comprises an optically detectable polypeptide or peptide.7. The method of claim 1 , wherein the detectable moiety is an antigenic peptide and ...

Подробнее
Номер записи: 65
11-04-2013 дата публикации

MONOCLONAL ANTIBODIES AGAINST HER2 ANTIGENS, AND USES THEREFOR

Номер: US20130089873A1
Автор: Alper Özge
Принадлежит: ALPER BIOTECH, LLC

The present invention provides and includes monoclonal antibodies (mAbs) preferentially selective for HER2 antigens, hybridoma lines that secrete these HER2 antibodies or antibody fragments, and the use of such antibodies and antibody fragments to detect HER2 antigens, particularly those expressed by cancer cells. The present invention also includes antibodies that are specific for or show preferential binding to a soluble or secreted form of HER2. The present invention also includes an antibody or antibody fragment that is capable of reducing the activity of HER2 in at least one form, including a soluble form or a secreted form. The present invention further includes chimeric antibodies, processes for producing monoclonal and chimeric antibodies or monoclonal or chimeric antibodies, and their therapeutic uses, particularly in the detection of cancer most preferentially in human breast, stomach, and colon. The present invention further includes methods and kits for the immunodetection and immunotherapy of cells for samples which express HER2 antigens. 150-. (canceled)51. A method of performing an immunoassay for a HER2 antigen in a biological sample , comprising: (a) contacting said biological sample with an antibody comprising a heavy chain variable domain comprising three complementarity determining regions (CDRs) comprising the amino acid sequences of SEQ ID NO: 2 , SEQ ID NO:3 , and SEQ ID NO:4 , and a light chain variable domain comprising three CDRs comprising the amino acid sequences of SEQ ID NO: 6 , Aspartic Acid-Threonine-Serine , and SEQ ID NO:7; and (b) qualitatively or quantitatively determining the formation of an immune complex of the antibody and the HER2 antigen.52. The method of claim 51 , wherein the biological sample comprises a human cancer cell selected from a breast claim 51 , stomach claim 51 , and colon cancer cell.53. The method of claim 51 , wherein the heavy chain amino acid sequence of the antibody comprises the sequence of SEQ ID NO: 1 ...

Подробнее
Номер записи: 66
11-04-2013 дата публикации

GLP-1 RECEPTOR AGONIST BIOASSAY

Номер: US20130089878A1
Автор: Bancroft Frederick Charles, Gupta Swati, Herich John Patrick, Lwin Aung Naing, Nicolaou Michalis
Принадлежит: Amylin Pharmaceuticals, LLC

Provided herein are cell-based bioassays for measuring GLP-I receptor agonist activity of test compounds, such as GLP-I receptor agonist compounds. Exemplary GLP-I receptor agonist compounds include exendins, exendin analogs, GLP-1(7-37), and GLP-1(7-37) analogs. The bioassays are useful for quantitatively determining cAMP generated in samples containing GLP-I receptor agonist compounds (e.g., exenatide) and 6-23 (clone 6) cells having GLP-I receptors, whereby the amount of cAMP generated can be correlated to the GLP-I receptor agonist activity of the GLPI receptor agonist compounds (e.g., exenatide). Suitable cell-based bioassays include enzyme-linked immunosorbent assays and homogeneous time-resolved fluorescence assays. 1. A method for detecting or measuring GLP-1 receptor agonist activity of a test compound comprising: (i) a test compound;', '(ii) 6-23 (clone 6) cells; and', '(iii) a detectably labeled cAMP;, '(a) preparing a sample comprising'}(b) forming a reaction mixture by combining the sample from step (a) and an anti-cAMP antibody;(c) quantitatively measuring cAMP in the sample; and(d) correlating the amount of cAMP in the sample to the GLP-1 receptor agonist activity of the test compound.2. The method of claim 1 , wherein the sample comprises:(i) a pharmaceutical composition which comprises the test compound;(ii) 6-23 (clone 6) cells; and(iii) a detectably labeled cAMP.3. The method of claim 1 , further comprising incubating the reaction mixture.4. The method of claim 1 , wherein the test compound is a GLP-1 receptor agonist compound.5. The method of claim 1 , wherein the test compound is exenatide.6. The method of claim 1 , wherein the test compound is liraglutide; albiglutide; taspoglutide; LY2189265; LY2428757; lixisenatide; CJC-1134; NN9535; [N-(17-carboxyheptadecanoic acid)Lys]exendin-4-NH; [N-(17-carboxy-heptadecanoyl)Lys]exendin-4-NH; [desamino-His claim 1 ,N-(17-carboxy-heptadecanoyl)-Lys]exendin-4-NH; [Arg claim 1 ,NLe claim 1 ,N-(17- ...

Подробнее
Номер записи: 67
11-04-2013 дата публикации

METHOD FOR DETECTING COMPOUNDS THAT MODULATE THE CHOLESTEROL METABOLISM

Номер: US20130090471A1
Автор: Dumas Bruno, Maury Isabelle
Принадлежит: SANOFI

The present invention relates to a method for identifying compounds that modulate cholesterol metabolism by detecting enzyme activities involved in the synthesis or catabolism of cholesterol. Said method enables the lethal risk for mammalian cells when the cholesterol level decreases to be avoided, due to the use of genetically modified yeasts, the survival of which is not strictly dependent upon the cholesterol production. 1. A method for identifying compounds that modulate cholesterol , characterized in that it comprises a cholesterol detection step and that the cholesterol level detected is inversely proportional to the growth of cells in a toxic medium.2. The method as claimed in claim 1 , characterized in that it comprises bringing a cholesterol-producing cell and a compound of interest into contact on a medium which is initially toxic for said cell.3. The method as claimed in claim 1 , characterized in that it comprises bringing a cell which produces both cholesterol and an enzyme that participates in cholesterol synthesis claim 1 , and a compound of interest into contact on a medium which is initially toxic for said cell.4. The method as claimed in claim 1 , characterized in that it comprises bringing a cell which produces both cholesterol and an enzyme that catabolizes cholesterol claim 1 , and a compound of interest into contact on a medium which is initially toxic for said cell.5. The method as claimed in claim 1 , characterized in that it comprises the use of cholesterol-producing genetically modified yeasts.6Saccharomyces cerevisae, Schizosaccharomyces pombe, KluyveromycesPichia pastoris. The method as claimed in claim 1 , characterized in that it comprises the use of yeasts included in the group consisting of: (lactis and the like) or claim 1 , said yeasts being genetically modified so as to produce cholesterol.7. The method as claimed in claim 1 , characterized in that it comprises the following steps:(a) transforming a yeast so that it expresses both ...

Подробнее
Номер записи: 68
18-04-2013 дата публикации

STAPHYLOCOCCUS AUREUS LEUKOCIDINS, THERAPEUTIC COMPOSITIONS, AND USES THEREOF

Номер: US20130095115A1
Автор: Dumont Ashley L., TORRES Victor J.
Принадлежит: New York University

Disclosed herein are isolated and purified bi-component leukocidin, referred to herein as LukAB, and its components LukA and LukB, antibodies specific to LukA, antibodies specific to LukB, therapeutic compositions containing LukA and/or LukB, or anti-LukA and/or anti-LukB antibodies, uses of the compositions to treat acute inflammatory conditions or infection, methods for identifying inhibitors of LukAB-mediated cytotoxicity of human phagocytes, and methods for using LukAB as a marker to predict severity of infection. 1Staphyloccocus aureus. An active agent useful in inhibiting onset of or treating a infection , comprising at least one of: a) a therapeutically effective amount of a LukA polypeptide having the amino acid sequence of any of SEQ ID NOS:1-14 , or a sequence having at least 70% sequence similarity to any of SEQ ID NOS:1-14 (“LukA”); b) a therapeutically effective amount of a LukB polypeptide having the amino acid sequence of any of SEQ ID NOS:15-27 , or a sequence having at least 70% sequence similarity to any of SEQ ID NOS:15-27 (“LukB”); c) a therapeutically effective amount of an anti-LukA antibody that specifically binds LukA; or d) a therapeutically effective amount of an antibody that specifically binds LukB.2. The active agent of claim 1 , wherein a) is a mature LukA polypeptide.3. The active agent of claim 1 , wherein a) comprises a LukA polypeptide that lacks the amino acid residues corresponding to positions 342-351 of any of SEQ ID NOs:1-14.4. The active agent of claim 1 , wherein b) is a mature LukB polypeptide.5Staphyloccocus aureus. A therapeutic composition for inhibiting onset of or treating a infection claim 1 , comprising the active agent of claim 1 , and a pharmaceutically acceptable carrier.6. The therapeutic composition of claim 5 , comprising therapeutically effective amounts of the anti-LukA antibody claim 5 , therapeutically effective amounts of the anti-LukB antibody claim 5 , or therapeutically effective amounts of the anti-LukA ...

Подробнее
Номер записи: 69
25-04-2013 дата публикации

Diagnostic Method for Predicting the Response of a Patient to Chemovirotherapy or Radiovirotherapy

Номер: US20130101989A1
Автор: Buechler Markus, Cziepluch Celina, DAEFFLER Laurent, GIESE Nathalia, Giese Thomas, RAYKOV Zahari, Rommelaere Jean, Werner Jens
Принадлежит:

Described is a diagnostic method for predicting the response of a patient to chemovirotherapy or radiovirotherapy, comprising exposing primary tumor cells from a patient, e.g., tumor cells obtained from a brain tumor or pancreatic cancer, to (i) a parvovirus and/or (ii) a chemotherapeutic agent or radiotherapy, and determining the reduction of the expression or concentration of ISG15. 1. A diagnostic method for predicting the response of a patient to chemovirotherapy or radiovirotherapy , comprising(a) exposing primary tumor cells of a tumor sample obtained from a patient to different doses of (i) a parvovirus and/or (ii) a chemotherapeutic agent or radiotherapy; and(b) determining the reduction of the expression or concentration of ISG15 over varying time periods.2. A method of selecting a therapy modality for a patient afflicted with a tumor , comprising(a) exposing primary tumor cells of a tumor sample obtained from a patient to different doses of (i) a parvovirus and/or (ii) a chemotherapeutic agent or radiotherapy; and(b) determining the reduction of the expression of concentration of ISG15 over varying time periods.3. The method of claim 1 , wherein said tumor is brain tumor or pancreatic tumor.4. The method claim 1 , wherein the expression of ISG15 is determined on the mRNA level.5. The method of claim 4 , wherein the mRNA level is determined by a hybridization based method or by PCR.6. The method of claim 1 , wherein the concentration of ISG15 is determined using an antibody that specifically binds to ISG15.7. A kit useful for carrying out a method of claim 1 , comprising an antibody that specifically binds to ISG15 or a probe or primer specifically hybridizing to ISG15 mRNA.8. The method of claim 2 , wherein said tumor is brain tumor or pancreatic tumor.9. The method claim 2 , wherein the expression of ISG15 is determined on the mRNA level.10. The method of claim 1 , wherein the concentration of ISG15 is determined using an antibody that specifically binds ...

Подробнее
Номер записи: 70
25-04-2013 дата публикации

COMPOSITION FOR THE DETERMINATION OF COAGULATION CHARACTERISTICS OF A TEST LIQUID

Номер: US20130102015A1
Автор: Schubert Axel
Принадлежит: C A CASYSO AG

The present invention is directed to a diagnostic composition for use in the viscoelastic analysis of a test liquid, and to a container () comprising same. The composition comprises at least an activator of coagulation, and at least one further constituent selected from CaCl2 and from one or more inhibitors and/or coagulation components, wherein the composition is present in essentially dry form of all constituents and in an amount sufficient for performing one single viscoelastic analysis of a specified blood or plasma sample and wherein the constituents are not present in a substance mixture, but in a spatially separated form. The present invention is further directed to a method of performing a viscoelastic analysis on a test liquid, and to the use of the diagnostic composition in such a method. 1. A diagnostic composition for use in the viscoelastic analysis of a test liquid , comprising at least two of the following constituents:a) one activator of coagulation; andb) a calcium salt in an amount sufficient to ensure recalcification of the test liquid; orc) one inhibitors or other coagulation components or factors;characterized in thatthe constituents are present in an essentially dry,and wherein the constituents are not present in a substance mixture, but in a spatially separated form.2. The composition according to claim 1 , where the spatial separation of the constituents is realized by incorporating each constituent into a separate carrier material.3. The composition according to claim 2 , where the carrier material comprises at least a carbohydrate.4. The composition according to claim 3 , where the carrier material shows no significant influence on the clotting behaviour claim 3 , the clot formation behaviour claim 3 , or the clot lysis behaviour.5. The diagnostic composition of claim 1 , wherein the activator of coagulation is an intrinsic or extrinsic activator.6. The diagnostic composition of claim 5 , wherein the extrinsic activator of coagulation is ...

Подробнее
Номер записи: 71
25-04-2013 дата публикации

Detection and Characterization of Protein Degradation, Protein Degradation Modulation and Protein Degradation Modulators

Номер: US20130102081A1
Автор: Paul Johann Andre Kenis, Ray Clifford Perkins, Sarah-Ellen Perkins Leonard
Принадлежит: Individual

Protein degradation, protein degradation modulation and protein degradation modulators can be detected and characterized through assessment of differential angular mobility exhibited by protein degradation reactants and products.

Подробнее
Номер записи: 72
25-04-2013 дата публикации

Sperm-Specific Cation Channel, Catsper1 and Uses Therefor

Номер: US20130102495A1
Автор: Clapham David E., REN Dejian
Принадлежит: CHILDREN'S MEDICAL CENTER CORPORATION

Nucleic acid and protein sequences relating to a cation channel which is sperm-specific (CatSper1) are disclosed. The CatSper1 protein is shown to be specifically expressed in sperm and to be necessary for sperm motility. Nucleic acids, vectors, transformed cells, transgenic animals, polypeptides, and antibodies relating to the CatSper1 gene and protein are disclosed. Also provided are methods of in vitro fertilization and contraception, methods of identifying modulators of CatSper1 activity, methods of genotyping subjects with respect to CatSper1, and methods of diagnosing and treating CatSper1-mediated disorders, including infertility. 140-. (canceled)41. A method of selecting a compound having potential contraceptive activity , the method comprising:(a) contacting a candidate compound with a cell expressing a CatSper1 protein;(b) measuring an indicator of CatSper1 expression or activity in said cell;(c) determining whether said candidate compound caused a change in said indicator relative to a reference level, wherein said change indicates a decrease in CatSper1 expression or activity in said cell; and(d) selecting said candidate compound that causes a decrease in sperm motility as having potential contraceptive activity.42. A method as in claim 41 , wherein said indicator is an indicator of the level of mRNA encoding said CatSper1 protein.43. A method as in claim 41 , wherein said indicator is an indicator of the level of CatSper1 protein.44. A method as in claim 41 , wherein said indicator is an indicator of cation flux across a membrane of said cell.45. A method as in claim 41 , wherein said indicator is an indicator of whole cell or channel currents of said cell.46. A method as in claim 41 , wherein said cell has been transformed with a genetic construct capable of expressing a CatSper1 protein.47111-. (canceled)112. A method of selecting a compound that inhibits sperm motility claim 41 , the method comprising:(a) contacting a candidate compound with a cell ...

Подробнее
Номер записи: 73
02-05-2013 дата публикации

ANALYTE MASS SPECTROMETRY QUANTITATION USING A UNIVERSAL REPORTER

Номер: US20130105684A1
Автор: DOMON Bruno, Duriez Elodie, Louette Joel, Peterman Scott M., Rogers John Charles
Принадлежит:

Quantitation of analytes, including but not limited to peptides, polypeptides, and proteins, in mass spectrometry using a labeled peptide coupled to a reporter, and a universal reporter. 1. A method of generating a dilution curve in a single injection into a liquid chromatograph/mass spectrometer , the method comprisinginjecting into a first liquid chromatography (LC) column coupled to a mass spectroscopy detection system a single peptide composition, each peptide in the composition having the identical amino acid sequence A whereby each amino acid is present in the composition as a heavy labeled isomer resulting in the composition being a sequence A blend of all heavy labeled isomers, each isomer in the blend of sequence A having a mass shift and each isomer in the blend of sequence A present in a different concentration,analyzing each peptide in the co-eluted peptide composition by mass spectroscopy, andgenerating from the single peptide composition injection of sequence A into the LC column a dilution curve from the analysis.2. The method of resulting a decreased loss of the less abundant isomer by non-specific binding to a component of the LC column due to the concentration of the most abundant isomer being higher than the concentration of the most diluted isomer.3. The method of further comprisinginjecting at least an additional sequence B and repeating the method, andcomparing the result of analysis of each of the sequence A blend and sequence B blend to compare to compare limits of detection (LOD), and limits of quantitation (LOQ) between different column injections.4. The method of further comprising{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'injecting the peptide composition from into a second liquid chromatography (LC) column coupled to a mass spectroscopy detection system apparatus and repeating the method, and'}comparing the result of analysis from each of the first column and second column to compare limits of detection (LOD), and limits of ...

Подробнее
Номер записи: 74
02-05-2013 дата публикации

PEPTIDE PROBES FOR DIAGNOSTICS AND THERAPEUTICS

Номер: US20130108549A1
Автор: Orser Cindy S., Rudolph Alan, Shivaprasad Shankarrama, Wegrzyn Renee
Принадлежит:

Disclosed are agents and methods that may be used to diagnose and treat a variety of diseases associated with conformationally-altered proteins. The agents and methods may be used to identify and deliver drugs useful for treating diseases associated with conformationally-altered proteins. 1. A method for identifying a target protein present in a specific state of self-aggregation in a sample , comprising:(a) contacting the sample with a peptide probe for the target protein, wherein the peptide probe preferentially binds to the target protein in a specific state of self-aggregation; and(b) detecting any binding between the peptide probe and any target protein present in the specific state of self-aggregation, thereby identifying any target protein present in the specific state of self-aggregation.2. The method of claim 1 , wherein the peptide probe preferentially binds to the target protein in a specific state of self-aggregation selected from the group consisting of monomers claim 1 , soluble oligomers claim 1 , and insoluble self-aggregates.3. The method of claim 2 , wherein the peptide probe preferentially binds to insoluble self-aggregates of the target protein selected from the group consisting of insoluble amorphous self-aggregates claim 2 , protofibrils claim 2 , and fibrils.4. The method of claim 1 , wherein target protein is selected from the group consisting of amyloid islet polypeptide precursor protein claim 1 , amyloid beta protein or Aβ peptide claim 1 , serum amyloid A claim 1 , insulin claim 1 , amylin claim 1 , non-amyloid beta component claim 1 , prions claim 1 , hemoglobin claim 1 , immunoglobulins or fragments thereof β-microglobulin claim 1 , α-synuclein claim 1 , rhodopsin claim 1 , α1-antichymotrypsin claim 1 , cystallins claim 1 , tau claim 1 , p53 claim 1 , presenilins claim 1 , low-density lipoprotein receptor claim 1 , apolipoproteins claim 1 , superoxide dismutase claim 1 , neurofilament proteins claim 1 , transthyretin claim 1 , ...

Подробнее
Номер записи: 75
02-05-2013 дата публикации

Methods for detecting cancer

Номер: US20130109592A1
Автор: Andrew Nicholas Lane, Michael Bousamra, Richard M. Higashi, Teresa Whei-Mei Fan
Принадлежит: University of Louisville Research Foundation ULRF

Methods to determine the absence or presence of one or more cancer types in an animal are disclosed herein. In some embodiments, amounts of lipids in a sample (e.g., a bodily fluid or treatment thereof) from the animal are used with a predictive model to make the determination. The lipid amounts can be measured, in some instances, using a mass spectrometry system.

Подробнее
Номер записи: 76
09-05-2013 дата публикации

METHOD FOR DETECTING MALIGNANT TUMOR CELLS

Номер: US20130115229A1
Автор: Bujo Hideaki, Ebinuma Hiroyuki, Fukamachi Isamu, Nakaseko Chiaki, Saito Yasushi, Takubo Kohei, Yoshida Saishu
Принадлежит: SEKISUI MEDICAL CO., LTD.

Provided is a detection method for a malignant tumor cell, including measuring a protein marker expressed on a malignant tumor cell surface. The detection method for a malignant tumor cell includes measuring LR11 on a cell surface in a sample to be tested. 1. A method of detecting a cell of a malignant tumor , comprising measuring LR11 on a cell surface in a sample to be tested.2. The method of claim 1 , wherein the malignant tumor is a hematopoietic tumor or a carcinoma.3. The method of claim 2 , wherein the malignant tumor is a hematopoietic tumor claim 2 , wherein the hematopoietic tumor is leukemia or malignant lymphoma.4. The method of claim 3 , wherein the hemapoietic tumor is leukemia claim 3 , wherein the leukemia is acute leukemia.5. The method of claim 3 , wherein the hematopoietic tumor is malignant lymphoma claim 3 , wherein the malignant lymphoma is non-Hodgkin's lymphoma.6. The method of claim 2 , wherein the malignant tumor is a carcinoma claim 2 , wherein the carcinoma is at least one selected from the group consisting of stomach cancer claim 2 , liver cancer claim 2 , pancreatic cancer claim 2 , lung cancer claim 2 , prostate cancer claim 2 , bladder cancer claim 2 , esophageal cancer claim 2 , breast cancer claim 2 , cervical cancer claim 2 , ovarian cancer claim 2 , colon cancer claim 2 , large bowel cancer claim 2 , kidney cancer claim 2 , gallbladder cancer claim 2 , neurotumor claim 2 , and malignant melanoma.7. The method of claim 1 , wherein the sample to be tested is peripheral blood claim 1 , a bone marrow aspirate claim 1 , or a tissue section.8. The method of claim 1 , wherein the measuring of LR11 on the cell surface comprises binding a protein to LR11 on the cell surface.9. The method of claim 8 , wherein the protein is an antibody or a receptor-associated protein.10. A method of diagnosing a malignant tumor claim 8 , the method comprising measuring LR11 on a cell surface in a sample to be tested.11. A therapeutic drug suitable for ...

Подробнее
Номер записи: 77
09-05-2013 дата публикации

PHOSPHOLIPID PROFILING AND CANCER

Номер: US20130115618A1
Автор: Swinnen Johan
Принадлежит: Katholieke Universiteit Leuven

In general, the present invention provides prognostic and predictive methods and kits for determining the lipogenicity of a tumor in a subject, by making use of phospholipid profiling, whereby a relative increase in mono-unsaturated phospholipid species in combination with a relative decrease in poly-unsaturated phospholipid species is indicative for a more resistant and aggressive lipogenic cancer phenotype. 1. An in vitro method for determining the lipogenicity of a tumor in a subject comprising determining the relative expression level of at least 1 mono-unsaturated phospholipid and at least 1 poly-unsaturated phospholipid in a tumor sample versus a normal sample; wherein an increase in relative expression level of said mono-unsaturated phospholipids and a decrease in relative expression level of said poly-unsaturated phospholipids is indicative for a more aggressive lipogenic phenotype.2. The in vitro method according to claim 1 , further comprising determining the relative expression level of at least 1 saturated phospholipid in said tumor sample versus said normal sample; wherein a decrease in the relative expression level of said saturated phospholipid claim 1 , an increase in relative expression level of said mono-unsaturated phospholipids and a decrease in relative expression level of said poly-unsaturated phospholipids is indicative for a more aggressive lipogenic phenotype.3. An in vitro method for determining the lipogenicity of a tumor in a subject comprising determining the expression level of at least 1 mono-unsaturated phospholipid and at least 1 poly-unsaturated phospholipid in a tumor sample and a normal sample; wherein an increased ratio of mono-unsaturated versus poly-unsaturated phospholipids in said tumor sample compared to said normal sample is indicative for a more aggressive lipogenic phenotype.4. An in vitro method for determining the lipogenicity of a tumor in a subject comprising determining the lipogenic profile of a tumor in a patient; ...

Подробнее
Номер записи: 78
09-05-2013 дата публикации

UBIQUITINATION ASSAY

Номер: US20130115619A1
Автор: Clark Jonathan Peter
Принадлежит:

The present invention related to a method of assaying ubiquitination in a sample by combining ubiquitin and two or more of E1, E2, E3 and a substrate protein in a sample under conditions suitable for ubiquitination to take place, exposing the sample with a labelled binding partner which is specific for the ubiquitin and measuring the amount of labelled ubiquitin bound to any one of the components in the sample, wherein one or more of the components in the sample comprises an immobilisation tag which facilitates its immobilisation onto a solid surface. 1. A method of assaying ubiquitination in a sample comprising: (i) ubiquitin;', 'two or more of:', '(ii) E1;', '(iii) E2;', '(iv) E3; and', '(v) a substrate protein;, 'a) combining in a sample under conditions suitable for ubiquitination to take placeb) exposing the sample with a labelled binding partner which is specific for the ubiquitin;c) measuring the amount of labelled ubiquitin bound to any one of components (ii) to (v) in the samplewherein one or more of components (ii), (iii), (iv), or (v) in the sample comprises an immobilisation tag which facilitates its immobilisation onto a solid surface.2. The method according to claim 1 , wherein all of components (ii) claim 1 , (iii) claim 1 , (iv) and (v) are combined in the sample.3. The method according to claim 1 , wherein more than one of components (ii) claim 1 , (iii) claim 1 , (iv) or (v) in the sample comprise an immobilisation tag claim 1 , and each tag is different.48-. (canceled)9. The method according to claim 1 , wherein the ubiquitin comprises a tag.10. The method according to claim 9 , wherein the ubiquitin tag is recognised by the labelled binding partner.11. (canceled)12. The method according to claim 9 , wherein the ubiquitin tag is capable of interacting with the labelled binding partner to produce a detectable signal.13. The method according to claim 12 , wherein the ubiquitin tag and labelled binding partner form a FRET pair.14. The method ...

Подробнее
Номер записи: 79
09-05-2013 дата публикации

HIGHLY SENSITIVE IMMUNOASSAYS AND ANTIBODIES FOR DETECTION OF BLOOD FACTOR VIII

Номер: US20130115621A1
Автор: Fass David N., Mann Kenneth G., Parhami-Seren Behnaz
Принадлежит: The University of Vermont and State Agriculture College

Disclosed are antibodies that selectively bind to blood coagulation factor FVIII, and highly sensitive immunological assays comprising these antibodies. Preferred assays can detect FVIII at about 3500-fold below the normal physiological levels, and have a wide array of applications including accurate monitoring of FVIII concentration in pharmaceutical products for treatment of blood coagulation disorders, and determination of FVIII levels in plasma of human patients, including those with blood coagulation disorders such as hemophilia. 1. A method for detecting a FVIII protein or a fragment thereof in a sample , comprising:(a) contacting a sample comprising FVIII protein with a reducing agent that releases FVIII from a FVIII-binding molecule;(b) contacting the sample of step (a) with a first (capture) antibody directed to a FVIII antigen such that the FVIII protein or fragment binds to said antibody and forms a complex therewith;(c) contacting the complex formed in step (b) with a second (probe) antibody directed to a FVIII antigen, said antibody being labeled with a detectable marker, to form a complex which includes the antibody of step (b), the FVIII protein or fragment, and the second antibody; and(d) detecting the second antibody in the complex formed in step (c), thereby detecting the FVIII protein or fragment in the sample.2. The method of claim 1 , wherein the sample comprises plasma.3. The method of claim 2 , wherein the plasma is obtained from a vertebrate subject.4. The method of claim 3 , wherein the subject is a human having or at risk of developing a blood clotting disorder.5. The method of claim 1 , wherein the sample is a pharmaceutical product comprising FVIII protein or a fragment thereof obtained from human blood.6. The method of claim 1 , wherein the sample comprises recombinant FVIII protein or a fragment thereof.7. The method of claim 1 , wherein the first and second antibodies can bind to FVIII under conditions wherein FVIII is dissociated from ...

Подробнее
Номер записи: 80
09-05-2013 дата публикации

METHOD FOR SELECTION OF CHEMOTHERAPEUTIC AGENTS FOR ADENOCARCINOMA CANCER

Номер: US20130115628A1
Автор: Isaacson Jeffrey Dean, Powell Eric L., Ranger-Moore James, Raponi Mical
Принадлежит:

The subject invention relates to determining the presence and level of hENT1 expression in tumor tissue that is appropriate for gemcitabine therapy, and more importantly, the level of hENT1 expression that signifies that treatment with a gemcitabine derivative is a more appropriate strategy. 1. A method for determining whether a gemcitabine derivative that is capable of being transported into the tumor tissue by a mechanism that is independent of the hENT1 protein is suitable for administration to a patient with cancer , comprising conducting an immunohistochemistry assay on a biological sample comprising cancer cells or cancer cell proteins from said patient to determine whether the hENT1 protein level is classified as Low , wherein said Low classification meets the criterion of having less than 50% of the cancer cells display hENT1 membrane staining with a hENT1 antibody upon examination with a 10× ocular of a light microscope , wherein if said immunohistochemistry assay indicates that the level of hENT1 protein is Low , the gemcitabine derivative that is capable of being transported into the tumor tissue by a mechanism that is independent of the hENT1 protein is suitable for administration to a patient with cancer.2. The method of claim 1 , wherein the cancer is pancreatic adenocarcinoma.3. The method of claim 1 , wherein said gemcitabine derivative is transported through the plasma membrane by a mechanism that does not utilize the hENT1 transporter.4. The method of claim 3 , wherein said mechanism of transport is by passive diffusion across the membrane.5. A method of classifying hENT1 biomarker expression in a tissue sample comprising:a) obtaining a tissue sample from a cancer patient;b) visualizing hENT1 biomarker protein expression in the tissue sample using immunohistochemical staining with an anti-hENT1 antibody;c) determining hENT1 protein staining intensity in the tissue sample; andd) classifying hENT1 biomarker expression as LOW when less than 50% of the ...

Подробнее
Номер записи: 81
16-05-2013 дата публикации

METHODS FOR PURIFYING ENDODERM AND PANCREATIC ENDODERM CELLS DERIVED FROM HUMAN EMBRYONIC STEM CELLS

Номер: US20130122520A1
Автор: Bang Anne, Kelly Olivia
Принадлежит: VIACYTE, INC.

The present disclosure relates to compositions and methods comprising cell surface markers for hES-derived cells, in particular, endoderm lineage cells including pancreatic endoderm-type cells, derived from hES cells. 1. A method of enriching for pancreatic endocrine cells comprising:a) exposing an in vitro cell population comprising pancreatic endocrine cells to a ligand that binds a cell-surface marker selected from the group consisting of CD200, CD318, CD142, CD57 and CD340; andb) selecting cells that bind to said ligand that binds the marker selected from the group consisting of CD200, CD318 and CD57 or selecting cells that do not bind to said ligand that binds the marker selected from the group consisting of CD142 and CD340, thereby enriching for pancreatic endocrine cells.2. The method of claim 1 , wherein said enriched pancreatic endocrine cells express chromogranin A.3. The method of claim 1 , wherein said enriched pancreatic endocrine cells express insulin.4. The method of claim 1 , wherein the ligand comprises an antibody or binding fragment thereof.5. The method of claim 1 , wherein said ligand is associated with a detectable label.6. The method of claim 1 , wherein said ligand is associated with a magnetic particle.7. The method of claim 1 , wherein said cells are separated by Fluorescence Activated Cell Sorting (FACS).8. The method of claim 1 , wherein said ligand binds CD318.9. The method of claim 8 , wherein the ligand comprises an antibody or binding fragment thereof.10. The method of claim 1 , wherein said ligand binds CD200.11. The method of claim 10 , wherein the ligand comprises an antibody or binding fragment thereof.12. The method of claim 1 , wherein said ligand binds CD57.13. The method of claim 12 , wherein the ligand comprises an antibody or binding fragment thereof.14. The method of claim 1 , wherein said ligand binds CD340.15. The method of claim 14 , wherein the ligand comprises an antibody or binding fragment thereof.16. The method of ...

Подробнее
Номер записи: 82
16-05-2013 дата публикации

Methods for Ionophorically Screening Pore Forming Bacterial Protein Toxins and Receptors

Номер: US20130122605A1
Автор: Cuppoletti John
Принадлежит:

A method for determining the amount of live pore forming bacterial toxin protein in a sample is provided, the method including the steps of a) forming a membrane comprising a lipid bilayer and a receptor, b) contacting the membrane with an ion solution and the sample, c) measuring ion flow through the membrane, d) comparing the ion flow through the membrane to a standard curve, and e) determining the amount of pore forming bacterial toxin protein in the sample. A kit for determining the amount of live pore forming bacterial toxin protein present in the sample is also provided. 115-. (canceled)16. A method for determining an amount of live pore forming bacterial toxin protein in a sample , comprising:a) forming a membrane comprising a lipid bilayer and a receptor in a receptacle comprising an aperture, such that the membrane forms across the aperture and provides separation between two compartments in the receptacle,b) contacting the membrane with an ion solution and the sample, wherein the sample comprises an amount of pore forming bacterial toxin protein, whereby the pore forming bacterial toxin protein binds the receptor and forms a pore in the membrane,c) measuring ion flow through the membrane,d) comparing the ion flow through the membrane measured in step (c) to a standard curve, ande) determining the amount of pore forming bacterial toxin protein in the sample based on the comparing of step (d),wherein the lipid bilayer comprises at least one of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylserine (POPS), 1,2-diphytanoyl-sn-glycero-3-phosphocholine, and cholesterol.17. The method of claim 16 , wherein the pore forming bacterial toxin protein in the sample comprises anthrax and the receptor comprises capillary morphogenesis 2 protein (CMG2).18. The method of claim 17 , wherein measuring ion flow through the membrane comprises measuring electric ...

Подробнее
Номер записи: 83
16-05-2013 дата публикации

Process for Ensuring Consistency and Reproducibility of a Diagnostic or Research Method

Номер: US20130123131A1
Автор: Ptacek Jason, Purvis Norman, Putta Santosh, ROSEN DAVID, Spellmeyer David, Westfall Matt
Принадлежит: NODALITY, INC.

A method is disclosed in which control processes are used to maintain consistency across a research or diagnostic series of steps. Some embodiments of the processes include the use of fresh or lyophilized cell lines, beads, surface or other markers. The use of quality control processes is intended to monitor data from the underlying methods in order to detect unacceptable variations and to allow for exclusion or normalization. Overlapping control processes allows for tighter control and for redundancy in the monitoring. 1. A functional , quality control method for flow cytometry or mass spectrometry , comprising the steps of:(a). Providing a microtiter plate;(b). Distributing sample cells into wells of the microtiter plate;(c). Distributing standard cells into wells of the microtiter plate;(d). Distributing rainbow control particles (RCPs) into wells of the microtiter plate;(e). Contacting the standard cells and sample cells with at least one modulator;(f). Measuring one or more activatable elements and one or more surface markers in the standard cells by flow cytometry or mass spectrometry to create standard cell data;(g). Measuring two activatable elements in the sample cells by flow cytometry or mass spectrometry to create test data;(h). Measuring RCPs by flow cytometry or mass spectrometry to create RCP data;(i). Comparing the standard cell data and RCP data to a preset range of acceptable values; and(j). Normalizing or excluding the test data when the standard cell data or the RCP data is not within the preset range of acceptable values.2. A functional , quality control method , for use in flow cytometry or mass spectrometry comprising the steps of:(a). Measuring at least two activatable elements in standard cells to create standard cell data;(b). Comparing the standard cell data to a preset range of acceptable values;(c). Measuring at least two activatable elements in sample cells to create test data; and(d). Excluding or normalizing test data when the ...

Подробнее
Номер записи: 84
16-05-2013 дата публикации

METHOD FOR THE CHARACTERIZATION OF INTERMOLECULAR INTERACTIONS

Номер: US20130123137A1
Автор: Etxebarria Ruiz Juan, Reichardt Niels-Christian
Принадлежит: CENTRO DE INVESTIGACIÓN COOPERATIVA EN BIOMATERIALS (CIC biomaGUNE)

The invention relates to a method for identifying in a sample molecules with the capacity to bind to the different members of a molecule library, wherein the molecules which are in the sample are fractionated based on a physicochemical property of the sample and subsequently transferred from the support in which said molecules have been separated to a second support in which the different members of the molecule library are grouped into microarrays such that they uniformly coat the surface of the support. This technique is especially interesting for the identification in a sample of glycoproteins with affinity for a lectin library as well as for the identification of compounds capable of modulating the glycosylation of proteins and for the rapid characterization of alterations in the glycosylation pattern of a sample of proteins, which can be useful in the diagnosis of diseases in which there are alterations in cell glycosylation. 115.-. (canceled)16. A method for determining presence in a population of molecules of at least one first member of a binding pair having the capacity to bind specifically to at least one second member of said binding pair , the method comprising:(i) fractionating the population of molecules in a first support based on at least one physicochemical property of said at least one first member of the binding pair, 'wherein said transferring of fractionated molecules is carried out under conditions suitable for maintaining in the second support a two-dimensional organization of the molecules fractionated in the first support and for allowing interaction between molecules of the population of molecules and the at least one second member of the binding pair coinciding spatially in the second support with said molecules, and', '(ii) transferring the fractionated molecules from said first support to a second support, wherein said second support is uniformly coated by a set of microarrays, wherein each microarray of the set of microarrays comprises ...

Подробнее
Номер записи: 85
23-05-2013 дата публикации

Means and Methods for Metabolic Differentiation of Non-Alcoholic Steatohepatitis From Liver Disease

Номер: US20130126722A1
Автор: Clemens Schafmayer, Dietrich Rein, Hennicke Kamp, Jens Fuhrmann, Jochen Hampe, Ulrike Rennefahrt
Принадлежит: Metanomics Health GmbH

The present invention relates to the field of diagnostic methods. Specifically, the present invention contemplates a method for diagnosing a liver disease in a subject and a method of differentiating between NASH and NAFLD. The invention also relates to tools for carrying out the aforementioned methods, such as diagnostic devices.

Подробнее
Номер записи: 86
23-05-2013 дата публикации

BILAYERS

Номер: US20130129910A1
Автор: Heron Andrew John, Holden Matthew Alexander, Wallace Mark Ian
Принадлежит: lsis Innovation Limited

A method for producing a bilayer of amphipathic molecules comprising providing a hydrated support and providing a hydrophilic body, and bringing the hydrated support and hydrophilic body into contact to form a bilayer of amphipathic molecules. A bilayer produced by the method of the invention, and uses of the bilayer. 27-. (canceled)8. The method of wherein the amphipathic molecules are lipid molecules.9. The method of wherein the lipid molecules are selected from the group comprising fatty acyls claim 8 , glycerolipids claim 8 , glycerophospholipids claim 8 , sphingolipids claim 8 , sterol lipids claim 8 , prenol lipids claim 8 , saccharolipids claim 8 , polyketides claim 8 , phospholipids claim 8 , glycolipids and cholesterol.10. The method of wherein the lipid molecules are selected from the group comprising monoolein; 1 claim 8 ,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC); 1 claim 8 ,2-diphytanoyl-sn-glycero-3-phosphatidylcholine (DPhPC); palmitoyl oleoyl phosphatidylcholine (POPC); 1-palmitoyl-2-oleoyl-phosphatidylethanolamine (POPE); 1-palmitoyl-2-oleoyl-phosphatidylethanolamine; and 1-palmitoyl-2-oleoylphosphatidylglycerol (POPE/POPG) mixtures; or mixtures thereof.11. (canceled)12. The method of wherein the hydrated support comprises a solid or a semi-solid substrate.13. The method of wherein the hydrated support is hydrophilic.14. (canceled)15. The method of wherein the hydrated support is selected from the group comprising hydrogels claim 1 , agarose claim 1 , polyacrylamide claim 1 , [cross-linked] polyethylene glycol claim 1 , nitro-cellulose claim 1 , polycarbonate claim 1 , anodisc material claim 1 , polyethersulphone claim 1 , cellulose acetate claim 1 , nylon claim 1 , Naphion materials claim 1 , mesoporous silica claim 1 , water and glass.16. The method of wherein the hydrated support is a protein or analyte separation gel.17. (canceled)18. The method of wherein the hydrophilic body comprises a droplet of aqueous solution.19. The method of wherein ...

Подробнее
Номер записи: 87
23-05-2013 дата публикации

IMMUNOASSAY METHODS AND REAGENTS FOR DECREASING NONSPECIFIC BINDING

Номер: US20130130275A1
Автор: Chiba Ryotaro, Yoshida Eisaku, Yoshimura Toru
Принадлежит: ABBOTT JAPAN CO., LTD.

Methods and kits for reducing non-specific binding in an immunoassay for PIVKA-II in a test sample are described, in which the test sample is reacted with an anti-prothrombin antibody in the presence of one or more of the following additives: skim milk, saponin, CaCl, MgCl, and a sulfobetaine zwitterionic detergent. 1. A method for measuring PIVKA-II in a test sample , the method comprising: reacting the test sample with an anti-prothrombin antibody in the presence of at least one additive selected from the group consisting of: skim milk , saponin , CaCl , MgCl , and a sulfobetaine zwitterionic detergent.2. The method of claim 1 , wherein the additives are provided in a diluent comprising the anti-prothrombin antibody and an effective amount of the at least one additive.3. The method of claim 1 , wherein the antibody comprises a monoclonal antibody.4. The method of claim 3 , wherein the antibody comprises MCA1-8.5. The method of claim 1 , wherein the reaction is performed on a solid phase.6. The method of claim 5 , wherein the solid phase comprises magnetic or paramagnetic microparticles.7. The method of claim 1 , wherein at least two additives are used including skim milk and saponin.8. The method of claim 1 , wherein the sulfobetaine zwitterionic detergent is selected from the group consisting of: Zwittergent® 3-14 (n-Tetradecyl-N claim 1 ,N-dimethyl-3-ammonio-1-propanesulfonate); Zwittergent® 3-16 (n-Hexadecyl-N claim 1 ,N-dimethyl-3-ammonio-1-propanesulfonate); Zwittergent® 3-18 (n-Octadecyl-N claim 1 ,N-dimethyl-3-ammonio-1-propanesulfonate); Zwittergent® ASB-14 (Amidosulfobetaine-14); and Zwittergent® ASB-16 (Amidosulfobetaine-16).9. The method of claim 8 , wherein the sulfobetaine zwitterionic detergent is selected from the group consisting of: Zwittergent® 3-14 (n-Tetradecyl-N claim 8 ,N-dimethyl-3-ammonio-1-propanesulfonate); Zwittergent® 3-16 (n-Hexadecyl-N claim 8 ,N-dimethyl-3-ammonio-1-propanesulfonate); Zwittergent® 3-18 (n-Octadecyl-N claim 8 ,N- ...

Подробнее
Номер записи: 88
23-05-2013 дата публикации

MAGNETIC IMMUNODIAGNOSTIC METHODS AND KIT FOR THE DEMONSTRATION OF ANTIBODY/ANTIGEN COMPLEXES IN ERYTHROCYTE BLOOD GROUPING AND PHENOTYPING

Номер: US20130130280A1
Автор: Barbreau Yves, Boulet Arnaud, Fauconnier Laurence, Zakhour Maha
Принадлежит: DIAGAST

The current invention relates to a magnetic immunodiagnostic method for the demonstration of antibody/antigen complexes of blood group and phenotype. Such a method involves the research and/or identification of antibodies or antigens, preferably anti-antigen antibodies or antigens of a blood group. This method implements a suspension of magnetic particles coated with an antibody anti-glycophorin A that can recognize and specifically magnetize erythrocytes. The invention also includes a device and kit for carrying out one such method. 155-. (canceled)56. Method for the magnetization of erythrocytes , said method consisting of the following steps:a) the coupling of antibody anti-glycophorin A (anti-GPA) on the surface of the magnetic particles, andb) the contact of magnetic particles coated with anti-GPA obtained step a) with erythrocytes.57. Method for the demonstration of a specific complex formed by reacting an anti-antigen antibody of blood group or phenotype , present in the solution , and a blood group or phenotype antigen carried by an erythrocyte , the said erythrocyte being bound to a magnetic particle , the reaction taking place in reactor with an open top and sealed base whose diameter decreases at least in the area close to the base in such a way that it forms an inclined wall being at least partially coated with an anti-immunoglobulin or with any other compound capable of binding to the antibody of the said formed complex , the said method consisting into several steps:a) prior to the contact between the magnetic particles suspension bearing the erythrocytes and the solution likely to contain anti-antigen antibodies from blood group or phenotype:filling of the reactor with a viscous solution such that to cover up at least part of the inclined wall of the reactor,b) bring into contact above the viscous solution contained in the reactor of the solution containing or likely to contain the said antibody with the suspension of magnetic particles bearing the ...

Подробнее
Номер записи: 89
23-05-2013 дата публикации

Markers for Renal Disease

Номер: US20130130285A1
Автор: Atkinson Michael Randolph, Yerramilli Mahalakshmi, Yerramilli Murthy V.S.N.
Принадлежит: IDEXX LABORATORIES, INC.

This invention provides reagents and methods for diagnosing renal disease. Differential levels of inosine metabolite, and proteins: apolipoprotein C-I, apolipoprotein C-II, fibrinogen alpha chain, or fibrinogen A-alpha chain, kininogen, Inter-Alpha Inhibitor H4 (ITIH4), keratin Type I cytoskeletol 10 cystatin A, cystatin B and other polypeptides and fragments thereof provide biomarkers of renal disease and are described herein. 1. A method for diagnosing renal disease , the method comprising:(a) determining the amount of at least one polypeptide in Table 1 in a patient sample, wherein said polypeptide(s) comprise one or more of SEQ ID NO: 1-SEQ ID NO: 59, and(b) comparing the amount of said at least one polypeptide in the patient sample to a control sample, wherein differential levels of polypeptide in a patient sample versus control sample is an indication of renal disease.2. The method of claim 1 , wherein said polypeptide is Apolipoprotein C-I claim 1 , Apolipoprotein C-II claim 1 , Kininogen claim 1 , Inter-Alpha Inhibitor H4 (ITIH4) claim 1 , Fibrinogen alpha-chain claim 1 , Fibrinogen A alpha-chain claim 1 , Cystatin A claim 1 , Cystatin B and/or Keratin Type I cytoskeletal 10 claim 1 , or a fragment thereof.3. The method of wherein determining the amount of polypeptide is performed by liquid chromatography/mass spectrometry (LC/MS).4. The method of wherein renal disease is glomerular.5. The method of wherein renal disease is tubular.6. The method of wherein the patient is a mammal.7. The method of wherein the patient is human claim 6 , feline claim 6 , or canine.8. The method of wherein the patient sample is blood claim 1 , serum claim 1 , plasma or urine.9. The method of wherein the polypeptide comprises SEQ ID NO: 1 claim 1 , 18 claim 1 , 23 claim 1 , 25 claim 1 , 31 claim 1 , or a combination thereof.10. The method of wherein determining the amount of polypeptide is performed by immunoassay.11. An isolated polypeptide comprising one or more of SEQ ID NO: 1 ...

Подробнее
Номер записи: 90
23-05-2013 дата публикации

METHODS FOR ASSESSING THE IMMUNE SYSTEM IN A PATIENT

Номер: US20130130286A1
Автор: Budhu Sadna, Clynes Raphael, Lee Peter P., Loike John D., Silverstein Samuel C.
Принадлежит: The Trustees of Columbia University in the City of New York

Methods of determining the onset or susceptibility of an immunological disease are provided herein. Also provided are immunoassay techniques for carrying out such methods. 1. An enzyme linked immunosorbent assay (ELISA) kit for determining the presence of soluble CD16b protein , which comprises at least one antibody specific to the protein to measure its molar ratio in a biological sample of a neutropenic patient , and wherein said molar ratio is indicative of the onset or susceptibility of sepsis in the patient.2. A method of predicting the onset of sepsis in a neutropenic patient claim 1 , the method comprising providing a biological sample from the patient; determining the presence of soluble CD16b protein in the biological sample; and predicting the onset of sepsis based on the presence or absence of soluble CD16b in the biological sample claim 1 , wherein the determining is carried out using an ELISA kit in accordance with .3. A method of detecting an increased susceptibility to sepsis in a neutropenic patient claim 1 , the method comprising providing a biological sample from the patient; determining the presence of soluble CD16b protein in the biological sample; and predicting the onset of sepsis based on the presence or absence of soluble CD16b in the biological sample claim 1 , wherein the determining is carried out using an ELISA kit in accordance with .4. A method of predicting the onset of sepsis in a neutropenic patient receiving a cancer treatment claim 1 , the method comprising providing a biological sample from the patient; determining the presence of soluble CD16b protein in the biological sample; and predicting the onset of sepsis based on the presence or absence of soluble CD16b in the biological sample.5. A method of detecting an increased susceptibility to sepsis in a patient receiving a cancer treatment claim 1 , the method comprising analyzing a biological sample from the patient for the presence of soluble CD16b protein claim 1 , wherein the ...

Подробнее
Номер записи: 91
23-05-2013 дата публикации

METHOD TO DETECT AND TREAT INFECTIOUS OR INFLAMMATORY DIARRHEA BASED ON REG1

Номер: US20130130965A1
Автор: JR. William A., Peterson Kristine, Petri
Принадлежит: UNIVERSITY OF VIRGINIA PATENT FOUNDATION

The present invention relates to methods for the diagnosis, treatment and prevention of infectious and/or inflammatory diarrhea. 1. A method for diagnosing infectious or inflammatory diarrhea comprising detecting the presence of Reg1 protein or mRNA in a fecal sample or intestinal biopsy from a subject , wherein the presence of Reg1 protein or mRNA in the fecal sample or intestinal biopsy indicates that the subject has infectious and/or inflammatory diarrhea.2. The method of claim 1 , wherein Reg1 protein is detected in the fecal sample.3. The method of claim 1 , wherein Reg1 protein or mRNA is detected in the intestinal biopsy.4. A method for diagnosing infectious or inflammatory diarrhea comprising obtaining a fecal sample from a subject claim 1 , determining the sample contains Reg1 protein claim 1 , and diagnosing the subject with infectious and/or inflammatory diarrhea.5. A method for diagnosing infectious or inflammatory diarrhea comprising obtaining an intestinal biopsy from a subject claim 1 , determining the biopsy contains Reg1 mRNA or protein claim 1 , and diagnosing the subject with infectious and/or inflammatory diarrhea.6. A method for determining if treatment of infectious or inflammatory diarrhea is efficacious comprising detecting the presence of Reg1 protein or mRNA in a fecal sample or intestinal biopsy from a subject claim 1 , wherein the presence of a reduced amount Reg1 protein or mRNA in the fecal sample or intestinal biopsy as compared to a sample from the subject taken earlier indicates that the treatment is effective.7. The method of claim 6 , wherein Reg1 protein is detected in the fecal sample.8. The method of claim 6 , wherein Reg1 protein or mRNA is detected in the intestinal biopsy.98. The method of any one of claim 6 , wherein Reg1 protein is detected by an immunological method which comprises contacting said sample with at least one reagent containing at least one antibody which binds to a Reg1 protein.10. The method of claim 9 , ...

Подробнее
Номер записи: 92
23-05-2013 дата публикации

METHODS OF USING A G PROTEIN-COUPLED RECEPTOR TO IDENTIFY PEPTIDE YY (PYY) SECRETAGOGUES AND COMPOUNDS USEFUL IN THE TREATMENT OF CONDITIONS MODULATED BY PYY

Номер: US20130131086A1
Автор: Chu Zhi-Liang, Jones Robert M., Leonard James N.
Принадлежит: ARENA PHARMACEUTICALS, INC.

The present invention relates to methods of using GPR119 receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY, such as conditions modulated by stimulation of NPY Y2 receptor (Y2R). Agonists of GPR119 receptor are useful as therapeutic agents for treating or preventing a condition modulated by PYY, such as a condition modulated by stimulation of Y2R. Conditions modulated by PYY such as may be a condition modulated by stimulation of Y2R include bone-related conditions, metabolic disorders, angiogenesis-related conditions, ischemia-related conditions, convulsive disorders, malabsorptive disorders, cancers, and inflammatory disorders. 1. A method of preparing a pharmaceutical composition comprising a G protein coupled receptor 119 (GPR119) agonist having the effect of a peptide YY (PYY) secretagogue , the method comprising:(a) administering a GPR119 agonist to a vertebrate; and(b) determining whether the GPR119 agonist increases a PYY level in the vertebrate, wherein the ability of the GPR119 agonist to increases a PYY level in the vertebrate is indicative of the GPR119 agonist being a PYY secretagogue; and(c) formulating the GPR119 agonist having the effect of a PYY secretagogue with a pharmaceutically acceptable carrier as a pharmaceutical composition.2. The method of claim 1 , wherein the GPR119 agonist is an agonist of human GPR119.3. The method of claim 1 , wherein the GPR119 agonist is orally available.4. The method of claim 1 , wherein the GPR119 agonist is a selective GPR119 agonist.5. The method of claim 1 , wherein the GPR119 agonist has a selectivity for GPR119 over a corticotrophin releasing factor-1 (CRF-1) receptor.6. The method of claim 1 , wherein the GPR119 agonist has an EC50 of less than 10 μM for elevating cyclic adenosine monophosphate (cAMP) in GPR119 transfected cells.7. The method of claim 1 , wherein the GPR119 agonist has an EC50 of less than 1 μM for elevating cAMP in GPR119 ...

Подробнее
Номер записи: 93
30-05-2013 дата публикации

INTEGRIN HETERODIMER AND A SUBUNIT THEREOF

Номер: US20130137118A1
Автор: Lundgren-Äkerlund Evy
Принадлежит: Xintela AB

A recombinant or isolated integrin heterodimer comprising a novel subunit α10 in association with a subunit β is described. The α10 integrin may be purified from bovine chondrocytes on a collagen-type-II affinity column. The integrin or the subunit of α10 can be used as a marker or target of all types of cells, e.g. of chondrocytes, osteoblasts, and fibroblasts. The integrin or the subunit α10 thereof can be used as a marker or target in different physiological or therapeutic methods. They can also be used as active ingredients in pharmaceutical compositions and vaccines. 1. A method of detecting a population of mammalian integrin subunit alpha10-expressing cells , said method comprising the steps of:a) contacting a cell suspension comprising an integrin subunit alpha10-expressing cell population with an antibody or a fragment thereof capable of binding to a fragment of the integrin subunit alpha10, wherein said integrin subunit alpha10 consists of amino acids 23-1167 of SEQ ID NO:4, andb) detecting said cell population binding to said antibody,thereby detecting a population of mammalian integrin subunit alpha10-expressing cells.2. The method according to claim 1 , wherein the fragment of the integrin subunit alpha10 consists of the extracellular domain of integrin subunit alpha10 claim 1 , wherein said extracellular domain of the integrin subunit alpha10 consists of amino acids 23-1120 of SEQ ID NO:4.3. The method according to claim 1 , wherein the fragment of the integrin subunit alpha10 consists of the transmembrane domain of the integrin subunit alpha10 claim 1 , wherein said transmembrane domain of the integrin subunit alpha10 consists of amino acids 1121-1145 of SEQ ID NO:4.4. The method according to claim 1 , wherein the fragment of the integrin subunit alpha10 comprises the cytoplasmic domain of the integrin subunit alpha10 claim 1 , wherein said cytoplasmic domain of the integrin subunit alpha10 consists of amino acid 1146-1167 of SEQ ID NO:4.5. The method ...

Подробнее
Номер записи: 94
30-05-2013 дата публикации

DIAGNOSTIC TEST TO EXCLUDE SIGNIFICANT RENAL INJURY

Номер: US20130137124A1
Автор: Bangert Kristian, Uttenthal Lars Otto
Принадлежит: AntibodyShop A/S

Methods for determining the risk of developing acute renal failure in a human subject by measuring human neutrophil gelatinase-associate lipocalin (NGAL) are provided. 2. The method of claim 1 , wherein the sample is a urine sample and the cutoff value is a concentration between 50 ng/mL and 250 ng/mL.3. The method of claim 1 , wherein the sample is a blood claim 1 , plasma or serum sample and the cutoff value is a concentration between 100 ng/mL and 250 ng/mL.4. The method of claim 1 , wherein the risk of developing acute renal failure is due to ischemic renal injury.5. The method of claim 1 , wherein the risk of developing acute renal failure is due to a complication of an inflammatory claim 1 , infective or neoplastic disease.6. The method of claim 1 , wherein the risk of developing acute renal failure is due to critical illness of any cause requiring intensive care.7. The method of claim 1 , wherein the risk of developing acute renal failure is due to a surgical intervention.8. The method of claim 1 , wherein the risk of developing acute renal failure is due to the administration of a nephrotoxic agent.9. The method of claim 1 , wherein NGAL is measured by means of a polyclonal or monoclonal antibody raised against NGAL.10. The method of claim 1 , comprising the further step of repeating steps i) and ii) of one or more times.11. The method of claim 1 , comprising the further step of repeating steps i) and ii) of within 24 hours.12. The method of claim 1 , comprising the further step of repeating steps i) and ii) of after a treatment of acute renal failure has been initiated or completed. The present invention relates to the identification of those individuals within a certain population or group of patients who, while being at general risk of suffering renal injury, do not have significant renal injury and are not at immediate risk of developing acute renal failure. As such it is relevant to internal medicine and in particular to critical or intensive care ...

Подробнее
Номер записи: 95
30-05-2013 дата публикации

Point of care immunization testing system

Номер: US20130137607A1
Автор: Sudip Ghatak
Принадлежит: Tracker LLC

A point of care immunization system based upon microfluidics and micro-titration technologies to rapidly test a patient in order to ascertain an immunization profile so that vaccinations can be administered to address identified gaps. A point of care system comprised of uniquely shaped and color distinguishing sample and test cartridges, with said test cartridges configured to meet healthcare requirements of national governing bodies. A point of care system including an easy access vaccine storage device with indicators to provide data on viability of stored vaccines.

Подробнее
Номер записи: 96
30-05-2013 дата публикации

PROTEIN BINDING DOMAINS STABILIZING FUNCTIONAL CONFORMATIONAL STATES OF GPCRS AND USES THEREOF

Номер: US20130137856A1
Автор: Fung Juan, Kobilka Brian, LAEREMANS Toon, Pardon Els, Rasmussen Søren, Steyaert Jan
Принадлежит:

The present invention relates to the field of GPCR structure biology and signaling. In particular, the present invention relates to protein binding domains directed against or capable of specifically binding to a functional conformational state of a G-protein-coupled receptor (GPCR). More specifically, the present invention provides protein binding domains that are capable of increasing the stability of a functional conformational state of a GPCR, in particular, increasing the stability of a GPCR in its active conformational state. The protein binding domains of the present invention can be used as a tool for the structural and functional characterization of G-protein-coupled receptors bound to various natural and synthetic ligands, as well as for screening and drug discovery efforts targeting GPCRs. Moreover, the invention also encompasses the diagnostic, prognostic and therapeutic usefulness of these protein binding domains for GPCR-related diseases. 1. A method of identifying a compound able to bind to a functional conformational state of a G protein-coupled receptor (GPCR) , said method comprising:(i) providing a GPCR and a protein binding domain able to specifically bind to a functional conformational state of said GPCR,(ii) providing a test compound,(iii) evaluating whether the test compound binds to the functional conformational state of the GPCR, and(iv) selecting a compound that binds to the functional conformational state of the GPCR.2. The method according to claim 1 , further comprising forming a complex comprising the protein binding domain and the GPCR in a functional conformational state.3. The method according to claim 2 , wherein the complex further comprises a receptor ligand.4. The method according to claim 3 , wherein said receptor ligand is selected from the group consisting of a small molecule claim 3 , a protein claim 3 , a peptide claim 3 , a protein scaffold claim 3 , a nucleic acid claim 3 , an ion claim 3 , a carbohydrate claim 3 , an ...

Подробнее
Номер записи: 97
06-06-2013 дата публикации

REAGENT AND REAGENT KIT FOR MEASUREMENT OF FDP, AND MEASUREMENT METHOD

Номер: US20130143243A1
Автор: KOBAYASHI Katsushi, MURAKAMI Masumi, SUGIMOTO Mayumi
Принадлежит: SYSMEX CORPORATION

The present invention relates to a reagent for the measurement of FDP comprising a carrier sensitized with at least two monoclonal antibodies selected from three monoclonal antibodies having different reactivity towards FDP. The present invention also relates to a reagent kit comprising the reagent and a method for measurement of FDP using the reagent or reagent kit. 1. A reagent for the measurement of FDP comprising a carrier sensitized with at least two monoclonal antibodies which have different reactivity towards FDP and are selected from:a first monoclonal antibody which does not react with the fragment D but reacts with the fragments XDP, DD/E, DD, X and Y;a second monoclonal antibody which does not react with the fragments X and D but reacts with the fragments XDP, DD/E, DD and Y; anda third monoclonal antibody which does not react with the fragment D but reacts with the fragments XDP, DD/E, DD, X and Y and has different reactivity towards FDP from that of the first monoclonal antibody.2. The reagent for the measurement of FDP according to claim 1 , wherein the carrier is carrier particles.3. The reagent for the measurement of FDP according to claim 2 , wherein the carrier particles are a mixture of carrier particles respectively sensitized with each monoclonal antibody.4. The reagent for the measurement of FDP according to claim 1 , wherein the first monoclonal antibody is an antibody produced by a hybridoma deposited with Incorporated Administrative Agency National Institute of Technology and Evaluation Patent Microorganisms Depositary on Jun. 1 claim 1 , 2010 under the accession number of NITE BP-950.5. The reagent for the measurement of FDP according to claim 1 , wherein the second monoclonal antibody is an antibody produced by a hybridoma deposited with Incorporated Administrative Agency National Institute of Technology and Evaluation Patent Microorganisms Depositary on Jun. 1 claim 1 , 2010 under the accession number of NITE BP-951.6. The reagent for the ...

Подробнее
Номер записи: 98
06-06-2013 дата публикации

DIAGNOSTIC METHOD FOR ENDOMETRIAL RECEPTIVITY

Номер: US20130144114A1
Автор: Berlanga Atienza Óscar, Pellicer Martínez Antonio, Simón Vallés Carlos
Принадлежит: Equipo IVI Investigación S.L.

The invention relates to a non-invasive diagnostic method of endometrial receptivity which includes collecting and comparing lipid biomarker patterns to reference lipidomic biomarkers, particularly prostaglandins PGE2 and/or PGF2α. The method is especially applicable for determining status fertility of a mammalian female, preferably, a woman. 1. A method for detecting endometrial receptivity to embryo implantation in a mammalian female comprising the steps of: 'performing an assay to determine a level of prostaglandin E2 (PGE2), prostaglandin F2 alpha (PGF2α), or both PGE2 and PGF2α in said endometrial fluid sample from said mammalian female; and', 'a) obtaining an endometrial fluid sample from said mammalian female;'}c) indicating in a report that said mammalian female is receptive to embryo implantation when the level of at least one of said prostaglandins PGE2 or PGF2α in said endometrial fluid sample is increased in relation to a reference sample.25-. (canceled)6. A method of in vitro fertilization in a mammalian female , said method comprising the steps of:a) obtaining endometrial fluid samples from a plurality of stages of the menstrual cycle of said mammalian female;b) performing an assay to determine level of prostaglandin E2 (PGE2), prostaglandin F2 alpha (PGF2α), or both PGE2 and PGF2α, in said endometrial fluid samples from said mammalian female; andd) introducing an embryo into the uterus of said mammalian female when the level of at least one of said prostaglandins PGE2 or PGF2α in said endometrial fluid samples is increased in relation to a reference sample.7. The method according to claim 1 , wherein said mammalian female is a woman.8. A method for identifying a compound capable of enhancing endometrium receptivity to embryo implantation claim 1 , comprising:a) contacting PGE2 and/or PGF2α, producing cells with a test compound;b) measuring at least a statistically significant increase in the production of said PGE2 and/or PGF2α by said cells in the ...

Подробнее
Номер записи: 99
13-06-2013 дата публикации

METHODS AND KITS FOR MEASURING VON WILLEBRAND FACTOR

Номер: US20130149716A1
Автор: Montgomery Robert
Принадлежит:

Methods and kits for measuring levels of von Willebrand factor function in a sample without using a platelet aggregation agonist, such as ristocetin, comprising recombinant glycoprotein Ibα having at least two of a G233V, D235Y and M239V mutations and an agent to detect a complex between the recombinant glycoprotein Ibα and von Willebrand factor. 1. A method of measuring von Willebrand factor (VWF) without using a platelet agglutination agonist , the method comprising the steps of: providing a surface comprising immobilized platelet glycoprotein Ibα (GPIbα) or a functional fragment thereof , wherein the immobilized GPIbα or functional fragment thereof comprises a combination of mutations selected from G233V , D235Y and M239V relative to SEQ ID NO:2; contacting a patient sample having or suspected of having VWF with the surface , wherein the contacting is done without a platelet aggregation agonist; and detecting a complex of VWF and GPIbα.2. The method of claim 1 , wherein the surface is a host cell surface claim 1 , and wherein the host cell does not natively express GPIbα.3Xenopus. The method of claim 2 , wherein the host cell for the host cell surface is selected from the group consisting of a oocyte claim 2 , a CHO-K1 cell claim 2 , a L929 cell claim 2 , a HEK-293T cell claim 2 , a COS-7 cell and a S2 cell claim 2 , and wherein the host cell is engineered to comprise a polynucleotide encoding the GPIbα or functional fragment thereof.4. The method of claim 2 , wherein the host cell surface also comprises glycoprotein Ibβ (GPIbβ) and optionally glycoprotein IX (GP-IX) claim 2 , wherein GPIbβ comprises SEQ ID NO:4 and GP-IX comprises SEQ ID NO:8.5. The method of claim 1 , wherein the surface is a solid-phase surface selected from the group consisting of agarose claim 1 , glass claim 1 , latex and plastic.6. The method of claim 5 , wherein the solid-phase surface comprises an anti-GPIba antibody that binds the GPIbα or functional fragment thereof.7. The method of ...

Подробнее
Номер записи: 100